ࡱ > d bjbj[[ 7t 9 9 8 + ` ` # # # # # # # # 8 $ & # 8y & ) ) ) ) * * * x x x x x x x $ T{ ~ ^ x # * * * * * x # # ) ) x aR aR aR * # ) # ) x aR * x aR aR R l o ) %áb K m x y 0 8y m d~ P d~ < o o d~ # u * * aR * * * * * x x mQ * * * 8y * * * * d~ * * * * * * * * * ` " : SEQ CHAPTER \h \r 1
CURRICULUM VITAE
Ashley E. Ross MD PhD
Texas Urology Specialists
DEMOGRAPHIC AND PERSONAL INFORMATION
Current Appointments
Urologist, Texas Urology Specialists
Previous Appointments
Associate Professor, Departments of Urology and Oncology, Johns Hopkins School of Medicine
Director, Johns Hopkins Urology Prostate Cancer Program
Chief Medical Advisor, GenomeDx Biosciences
Education and Training
Undergraduate
8/1994 5/1997 B.S., Biochemistry
University of Maryland, College Park
Doctoral/Graduate
7/1997 5/2006 Doctor of Medicine
Doctor of Philosophy, Mentor Dr. Stephen V. Desiderio
MD / PhD, Medical Scientist Training Program
Johns Hopkins University School of Medicine,
Biochemistry, Cellular and Molecular Biology Program
Baltimore, MD
Post-doctoral
7/2006-6/2007 Intern- Johns Hopkins Medical Institution, Department of Surgery
Chair: Julie A. Freischlag
7/2007-6/2009 Resident- Johns Hopkins Medical Institution, Department of Urology
Chair: Alan W. Partin MD PhD
7/2009-6/2010 Post-Doctoral Research Fellowship, Departments of Urology, Oncology and Pathology, Johns Hopkins Medical Institution
Mentor: Edward M. Schaeffer MD PhD
7/2010-6/2012 Chief Resident, Johns Hopkins Medical Institution, Department of
Urology
Chair: Alan W. Partin MD PhD
Professional Experience
7/2012-12/2016 Assistant professor Urology, Oncology, Pathology, Johns Hopkins School
of Medicine, Baltimore, MD
12/2015-2/2017 Director, Johns Hopkins Urology Prostate Cancer Program
12/2016-4/2017 Associate professor Urology and Oncology, Johns Hopkins School of Medicine, Baltimore, MD
3/2017-present Chief Medical Advisor, GenomeDx Biosciences
7/2017-present Urologist, Texas Urology Specialists
PUBLICATIONS:
Original Research [OR]
Tretter T, Ross AE*, Dordai DI, Desiderio S. Mimicry of pre-B cell receptor signaling by activation of the tyrosine kinase Blk. J Exp Med. 2003 Dec 15; 198(12): 1863-73.
*Equal contribution first authorship.
Ross AE, Vuica M, Desiderio S. Overlapping signals for protein degradation and nuclear localization define a role in intrinsic RAG-2 nuclear uptake in dividing cells. Mol Cell Biol. 2003 Aug;23(15):5308-19.
Jiang H, Ross AE, Desiderio S. Cell cycle-dependent accumulation in vivo of transposition-competent complexes between recombination signal ends and full-length RAG proteins. J Biol Chem. 2004 Feb 27;279(9): 8478-86.
Jiang H, Chang FC, Ross AE, Lee J, Nakayama K, Nakayama K, Desiderio S. Ubiquitylation of RAG-2 by Skp2-SCF links destruction of the V(D)J recombinase to the cell cycle. Mol Cell 2005 Jun 10;18(6): 699-709.
Ross AE, Handa S, Lingeman JE, Matlaga BR. Kidney stones during pregnancy: an investigation into stone composition. Urol Res. 2008 May; 36(2): 99-102.
Loeb S, Epstein JI, Ross AE, Shultz L, Humphreys EB, Jarow JP. Benign prostate glands at the bladder neck margin in robotic vs open radical prostatectomy. BJU Int 2010 Mar 25.
Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Ketterman A, Feng Z, Carter HB, Walsh PC. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010 Jun 10;28(17):2810-6.
Bivalacqua TJ, Ross AE, Strong TD, Gebska MA, Musicki B, Champion HC, Burnett AL. Attenuated RhoA/Rho-Kinase signaling in the penis of transgenic sickle cell mice. Urology. 2010 Aug: 76(2):510.e7-12.
Emadi A, Ross AE, Cowan KM, Fortenberry YM, Vuica-Ross M. A chemical genetic screen for modulators of asymmetrical 2,2-dimeric naphthoquinone cytotoxicity in yeast. PLoS ONE 2010, May 26;5(5):e10846.
Cilip CM, Ross AE, Jarow J, Fried NM. Application of an optical clearing agent during noninvasive laser coagulation of the canine vas deferens. J Biomed Opt. 2010 Jul-Aug; 15(4):04001.
Ross AE, Emadi A, Marchionni L, Hurley PJ, Simons BW, Schaeffer EM, Vuica-Ross M. Dimeric napthoquinones, a novel class of compounds with prostate cancer cytotoxicity. BJU Int. 2010 Dec 22.
Ross AE, Marchionni L, Vuica-Ross M, Cheadle C. Fan J, Berman DM, Schaeffer EM. Gene expression pathways of high grade localized prostate cancer. Prostate 2011, Feb 25.
Pierorazio PM, Ross AE, Schaeffer EM, Epstein JI, Han M, Walsh PC, Partin AW. A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy. J Urol 2011. May; 185(5): 1691-7.
Ross AE, Marchionni L, Phillips TM, Miller RM, Hurley PJ, Simons BW, Salmasi AH, Schaeffer AJ, Gearhart JP, Schaeffer EM. Molecular effects of genistein on male urethral development. J. Urol 2011. May; 185(5):1894-8.
Loeb S, Feng Z, Ross AE, Trock BJ, Humpreys EB, Walsh PC. Can we stop prostate-specific antigen testing 10 years after radical prostatectomy? J Urol 2011. Aug; 186(2): 500-5.
Pierorazio PM, Ross AE, Han M, Epstein J, Walsh PC, Partin A, Schaeffer EM. Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer. BJUI 2011, Aug 22.
Cilip CM, Pierorazio PM, Ross AE, Allaf ME, Fried NM. High-frequency ultrasound imaging of non-invasive laser coagulation of the canine vas deferens. Lasers Surg Med. 2011 Sep: 43(8): 838-42.
Emadi A, Le A, Harwood CJ, Stagliano KW, Kamangar F, Ross AE, Cooper CR, Dang CV, Karp JE, Vuica-Ross M. Metabolic and electrochemical mechanisms of dimeric naphthoquinones in cytotoxicity in breast cancer cells. Bioorg Med Chem. 2011 Dec 1: 19(23): 7057-62.
Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM. Effects of treatment with 5-Alpha reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU Int. 2012 Jan 30.
Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int. 2012 Feb28.
Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, Schaeffer EM. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget 2012 Jul 2.
Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, Berman DM, Schaeffer EM. Secreted protein, acidic and rich in cystein-like 1 (SPARCL1) is down regulated in aggressive prostate cancer and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14977-82. Epub 2012 Aug 27.
Simons BW, Hurley PJ, Huang Z, Ross AE, Miller R, Marchionni L, Berman DM, Schaeffer EM. Wnt signaling through beta-catenin is required for prostate lineage specification. Dev Biol. 2012 Aug 30.
Sundi D, Ross AE, Humphreys E, Han M. Partin AW, Carter HB, Schaeffer EM. African American men with very low risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy. Is active surveillance still an option? JCO 2013 Aug 20(24)2991-7.
Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, Han M, Epstein JI, Partin AW, Walsh PC, Bivalacqua TJ. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. Prostate 2013 Sept 9.
Pierorazio PM, Mullins JK, Ross AE, Hyams ES, Partin AW, Han M, Walsh PC, Schaeffer EM, Pavlovich CP, Allaf ME, Bivalacqua TJ. Trends in immediate peri-operative morbidity and delay in discharge after open and minimally invasive radical prostatectomy (RP): a 20-year institutional experience. BJU Int 2013 Jul; 112 (1):45-53.
Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM, Ross AE. Very high risk localized prostate cancer: definition and outcomes. PCPD 2014. March 17(1): 57-63.
Ross AE, Feng FY, Chadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson JS, Triche T, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes J, Schaeffer EM. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. PCPD 2014. March 17(1): 64-9.
Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer ME. Pathological examination of radical prostatectomies in men with very-low-risk disease at biopsy reveals distinct zonal distribution of cancer in African American men. J Urol. 2014. 191(1):60-7.
Levy DA, Ross AE, Elshafei A, Krishnan N, Hatem A, Jones JS. Definition of biochemical success following whole gland cryoablation. J Urol 2014. May 9.
Faisal FA, Sundi D, Pierorazio PM, Ball MW, Humphreys EB, Han M, Epstein JI, Partin AW, Carter HB, Bivalacqua TJ, Schaeffer EM, Ross AE. Outcomes of men with an elevated PSA as their sole pre-operative intermediate or high risk feature. BJU Int 2014. April 15
Sundi D, Wang V, Pierorazio PM, Han M, Partin AW, Tran PT, Ross AE, Bivalacqua TJ. Identification of men with the highest risk of early disease recurrence after radical prostatectomy. Prostate 2014. May 7.
Sundi D, Cohen JE, Cole AP, Neuman BP, Cooper J, Faisal FA, Ross AE, Schaeffer EM. Establishment of a new prostate cancer muti-disciplinary clinic: format and initial experience. Prostate 2015; 75(2): 191-9.
Simons BW, Durham NM, Bruno TC, Grosso JF, Schaeffer AJ, Ross AE, Hurley PJ, Berman DM, Drake CG, Thumbikat P, Schaeffer EM. A human prostatic bacterial isolate alters the prostate microenvironment and accelerates prostate cancer progression. J Pathol. 2015; Feb; 235(3): 478-89.
Faisal FA, Sundi D, Cooper JL, Humphreys EB, Partin AW, Han M, Ross AE, Schaeffer EM. Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up. Uroloy 2014 84(6); 1434-41.
Sundi D, Faisal FA, Trock BJ, Landis PK, Feng Z, Ross AE, Carter HB, Schaeffer EM. Reclassification rates are higher among African American men than Caucasians on active surveillance. Urology. 2015 85(1): 155-60.
Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/25964175" Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes.Eur Urol. 2015 May 8. [Epub ahead of print].
Ross AE, Yousefi K, Davicioni E, Ghadessi M, Johnson MH, Sundi D, Tosoian JJ, Han M, Humphreys EB, Partin AW, Walsh PC, Trock BJ, Schaeffer EM. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate and High Risk Men.Eur Urol. 2015 Apr 25. [Epub ahead of print].
Carvalho FL, Marchionni L, Gupta A, Kummangal BA, Schaeffer EM, Ross AE, Berman DM. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/25864518" HES6 promotes prostate cancer aggressiveness independently of Notch signalling.J Cell Mol Med. 2015 Apr 12. [Epub ahead of print].
Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, Davicioni E, Feng FY. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/25986914" High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.Prostate Cancer Prostatic Dis. 2015 May 19. [Epub ahead of print].
Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humpreys EB, Faraj S, Bezerra, Han M, Partin AW, Trock BJ, Schaeffer EM. Tissue Based Genomics Augment Post-Prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology. Eur Urol 2015 Jun 6.
Hurley PJ, Hughes RM, Simons B, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kinura Y, Jabbari J,Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, Netto GJ, Yegnasubramanian S, An S, Schaeffer E. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26294211" Androgen Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. Cancer Res. 2015 Oct 15; 75(20): 4322-34.
Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z,Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26195723" Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol. 2015 Sep 1;33(25):2789-96. Epub 2015 Jul 20.
Hurley PJ, Sundi D, Shinder B, Simons B, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing CM, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An S, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer E. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26446945" Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment and are Differentially Associated with Metastatic Prostate Cancer.
Clin Cancer Res. 2015 Oct 7. pii: clincanres.0256.2015.
Faisal FA, Sundi D, Tosoian JJ, Choeurng V, Alshalalfa M, Ross AE, Klein E, Den R, Dicker A, Erho N, Davicioni E, Lotan TL, Schaeffer EM. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26443432" Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. Eur Urol. 2015 Oct 3
Tay KJ, Polascik TJ, Elshafei A, Cher ML, Given RW, Mouraviev V, Ross AE, Jones JS. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26414656" Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. J Endourol. 2015 Oct 20.
Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, Feng FY. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26631616" The landscape of prognostic outlier genes in high-risk prostate cancer. Clin Cancer Res. 2015 Dec 2.
Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis E, Eisenberger M, Carducci M, Ross A, Kantoff P, Holt DP, Dannals RF, Mease RC, Pomper MG, Cho SY. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26493203" Comparison of PSMA-based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer. J Nucl Med. 2015 Oct 22.
Faraj SF, Bezerra SM, Yousefi K, Fedor H, Glavaris S, Han M, Partin AW, Humphreys E, Tosoian J, Johnson MH, Davicioni E, Trock BJ, Schaeffer EM, Ross AE, Netto GJ. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26731672" Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. PLoS One. 2016 Jan 5;11(1).
Schwen ZR, Tosoian JJ, Sokoll LJ, Mangold L, Humphreys E, Schaeffer EM, Partin AW, Ross AE. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26688190" Prostate Health Index (PHI) Predicts High-stage Pathology in African American Men. Urology. 2015 Dec 10.
Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, Karnes RJ, Schaeffer EM. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer Prostatic Dis. 2016. May 3.
You S, Knudsen BS, Erho N, Alshalalfa M, Takar M, Al-Deen Ashab H, Davicioni E, Karnes RJ, Klein EA, Den RB, Ross AE, Schaeffer EM, Garraway IP, Kim J, Freeman MR. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Res. 2016 Jun 14.
Johnson MH, Ross AE, Alshalalfa M, Erho N, Yousefi K, Glavaris S, Fedor H, Han M, Faraj SF, Bezerra SM, Netto G., Partin AW, Trock BJ, Davicioni E, Schaeffer EM. SPINK1 define a molecular subtype of prostate cancer in men with more rapid progression in a at-risk natural history radical prostatectomy cohort. J Urol 2016. May 26.
Ghabili K, Tosoian JJ, Schaeffer EM, Pavlovich CP, Golzari SE, Khajir G, Andreas D, Benzon B, Vuica-Ross M, Ross AE. The History of Prostate Cancer From Antiquity: Review of Paleopathological Studies. Urology. 2016 Aug 31.
Klein EA, Santiago-Jimenez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, Freedland SJ, Ross AE. Molecular analysis of low grade prostate cancer utilizing a genomic classifier of metastatic potential. J Urol 2016. Aug 25
Tosoian JJ, Almutairi F, Morais GL, Glavaris S, Hicks J, Sundi D, Humphreys E, Han M, De Marzo AM, Ross AE, Tomlins SA, Schaeffer EM, Trock BJ, Lotan TL. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American men Undergoing Radical Prostatectomy. Eur Urol 2016 Jul 28.
Shukla S, Zhang X, Niknafs YS, Xiao L, Mehra R, Cleslik M, Ross A, Schaeffer E, Malik B, Guo S, Freier SM, Bui HH, Siddiqui J, Jing X, Cao X, Dhanasekaran SM, Feng FY, Chinnaiyan AM, Malik R. Identification and Validation of PCAT14 as a Prognostic Biomarker in Prostate Cancer. Neoplasia 2016 Aug: 18(8): 489-99.
Benzon, B, Zhao SG, Haffner M, Takhar M, Erho N, Yousef K, Hurley P, Bishop J, Tosoian J, Ghabili K, Alshalafa M, Glavaris S, Simons B, Tran P, Davicioni E, Karnes RJ, Boudadi K, Antonarakis E, Schaeffer EM, Drake CG, Feng F, Ross AE. Correlation of B7-H3 with Androgen Receptor, Immune Pathways and Poor Outcomes in Prostate Cancer: An Expression Based Analysis. PCPD 2016 Nov 1. Epub ahead of print.
Guedes LB, Tosoian JJ, Hicks J, Ross AE, Lotan TL. PTEN Loss in Gleason Score 3+4=7 Prostate Biopsies is Associated with Non-Organ Confined Disease at Radical Prostatectomy. J Urol 2016 Sep 27. Epub ahead of print.
Zhao, SG. Chang L, Spratt DE, Erho, N, Yu M, Ashab HA; Alshalalfa M, Speers C, Tomlins S, Davicioni E, Dicker AP, Carroll PR, Cooperberg M, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng F. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched retrospective analysis. Lancet Oncol 2016 Oct 12. Epub ahead of print.
Tosoian JJ, ALam R, Gergis C, Narang A, Radwan N, Robertson S, McNutt T, Ross AE, Song DY, DeWeese TL, Tran PT, Walsh PC. Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease. Prostate Cancer Prostatic Dis. 2017 Jan 3. Epub ahead of print.
Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson A, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ,RossAE, Den RB, Klein EA, Chi KN, Ramshaw HS, Williams ED, Zoubedi A, Goodall GJ, Feng FY, Butler LM, Tilley WD, Selth LA. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2.
Cancer Res. 2016 Dec 23. pii: canres.2529.2016. doi: 10.1158/0008-5472.CAN-16-2529. [Epub ahead of print]
Li X, Rowe SP, Leal JP, Gorin MA, Allaf ME,RossAE, Pienta KJ, Lodge MA, Pomper MG. Quantitative Parameters in PSMA-targeted PET Imaging with 18F-DCFPyL: Variability in Normal Organ Uptake. J Nucl Med. 2016 Dec 8. pii: jnumed.116.179739. [Epub ahead of print]
Maughan BL, Suzman DL, Luber B, Wang H, Glavaris S, Hughes R, Sullivan R, Harb R, Boudadi K, Paller C, Eisenberger M, Demarzo A, Ross AE, Antonarakis ES. Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2016 Dec; 78(6): 1297-1304.
Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28494073" Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 May 11. doi: 10.1001/jamaoncol.2017.0751. [Epub ahead of print] PMID:28494073
Malek R, Gajula RP, Williams RD, Nghiem B, Simons BW, Nugent K, Wang H, Taparra K, Lemtiri-Chlieh G, Yoon AR, True L, An SS, DeWeese TL, Ross AE, Schaeffer EM, Pienta KJ, Hurley PJ, Morrissey C, Tran PT. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28484075" TWIST1-WDR5-Hottip regulates Hoxa9 chromatin to facilitate prostate cancermetastasis. Cancer Res. 2017 May 8. pii: canres.2797.2016. doi: 10.1158/0008-5472.CAN-16-2797. [Epub ahead of print] PMID:28484075
Tosoian JT, Chappidi MR, Bishoff JT, Freedland SJ, Reid J, Brawer M, Stone S, Schlomm T, Ross AE. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28481440" Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with NCCN Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance. BJU Int. 2017 May 8. doi: 10.1111/bju.13911. [Epub ahead of print] PMID:28481440
Guedes L, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S, Zoino R, Yousefi K, Sharma R, De Marzo AM, Netto G, Isaacs WB, Ross AE, Schaeffer EM, Lotan TL. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28446506" Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer. Clin Cancer Res. 2017 Apr 26. pii: clincanres.0257.2017. doi: 10.1158/1078-0432.CCR-17-0257. [Epub ahead of print]PMID:28446506
Nyame YA, Elshafei A, Greene DJ, Arora HC, Given RW, Tay KJ, Polascik TJ, Ross AE, Mouraviev VB, Lugnani F, Jones JS. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28437170" Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation. J Endourol. 2017 May;31(5):497-501. doi: 10.1089/end.2016.0715. PMID:28437170
Tosoian JJ, Patel HD, Mamawala M, Landis P, Wolf S, Elliott DJ, Epstein JI, Carter HB, Ross AE, Sokoll LJ, Pavlovich CP. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28417979" Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance. Prostate Cancer Prostatic Dis. 2017 Apr 18. doi: 10.1038/pcan.2017.16. [Epub ahead of print] PMID:28417979
Karnes RJ, Choeurng V, Ross AE, Schaeffer EM, Klein EA, Freedland SJ, Erho N, Yousefi K, Takhar M, Davicioni E, Cooperberg MR, Trock BJ. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28400167" Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. 2017 Apr 8. pii: S0302-2838(17)30264-6. doi: 10.1016/j.eururo.2017.03.036. [Epub ahead of print] PMID: 28400167
Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LL, du Plessis M, Choeurng V, Haddad Z, Buerki C, Davicioni E, Weinmann S, Freedland SJ, Klein EA, Karnes RJ, Feng FY. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28358655" Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. J Clin Oncol. 2017 Mar 30:JCO2016702811. doi: 10.1200/JCO.2016.70.2811. [Epub ahead of print] PMID: 28358655
Dalela D, Santiago-Jimnez M, Yousefi K, Karnes RJ, Ross AE, Den RB, Freedland SJ, Schaeffer EM, Dicker AP, Menon M, Briganti A, Davicioni E, Abdollah F. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28350520" Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. J Clin Oncol. 2017 Mar 28:JCO2016699918. doi: 10.1200/JCO.2016.69.9918. [Epub ahead of print] PMID:28350520
Torres A, Alshalalfa M, Tomlins SA, Erho N, Gibb EA, Chelliserry J, Lim L, Lam LLC, Faraj SF, Bezerra SM, Davicioni E, Yousefi K, Ross AE, Netto GJ, Schaeffer EM, Lotan TL. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28341589" Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. J Mol Diagn. 2017 May;19(3):475-484. doi: 10.1016/j.jmoldx.2017.01.007. Epub 2017 Mar 21. PMID: 28341589
Mo F, Lin D, Takhar M, Ramnarine VR, Dong X, Bell RH, Volik SV, Wang K, Xue H, Wang Y, Haegert A, Anderson S, Brahmbhatt S, Erho N, Wang X, Gout PW, Morris J, Karnes RJ, Den RB, Klein EA, Schaeffer EM, Ross A, Ren S, Sahinalp SC, Li Y, Xu X, Wang J, Wang J, Gleave ME, Davicioni E, Sun Y, Wang Y, Collins CC. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28330676" Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. Eur Urol. 2017 Mar 19. pii: S0302-2838(17)30166-5. doi: 10.1016/j.eururo.2017.02.038. [Epub ahead of print] PMID: 28330676
Alshalalfa M, Verhaegh GW, Gibb EA, Santiago-Jimnez M, Erho N, Jordan J, Yousefi K, Lam LL, Kolisnik T, Chelissery J, Seiler R, Ross AE, Karnes RJ, Schaeffer EM, Lotan TT, Den RB, Freedland SJ, Davicioni E, Klein EA, Schalken JA. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28187449" Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: Exploratory analysis from 12,076 patients. Oncotarget. 2017 Feb 7. doi: 10.18632/oncotarget.15133. [Epub ahead of print] PMID: 28187449
Kim H, Kalchman I, Santiago-Jimnez M, Lehrer J, Guo J, Hermann G, Yamoah K, Alshalalfa M, Huang HC, Ross AE, Schaeffer EM, Davicioni E, Erho N, Yousefi K, Den RB. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28140459" Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. Cancer. 2017 Jan 31. doi: 10.1002/cncr.30580. [Epub ahead of print] PMID:28140459
Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Agostino J, Macura KJ, Carter HB, Schaeffer EM, Partin AW, Sokoll LJ, Ross AE. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28117387" Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. Prostate Cancer Prostatic Dis. 2017 Jun;20(2):228-233. doi: 10.1038/pcan.2016.72. Epub 2017 Jan 24. PMID: 28117387
Tse BW, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, Erho N, Alshalafa M, Davicioni E, Schaeffer EM, Jenkins RB, Ross AE, Karnes RJ, Den RB, Fazli L, Gregory PA, Gleave ME, Williams ED, Rennie PS, Buttyan R, Gunter JH, Selth LA, Russell PJ, Nelson CC, Hollier BG. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28092670" Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.482. [Epub ahead of print] PMID: 28092670
Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Mamawala M, Agostino J, Carter HB, Partin AW, Sokoll LJ, Ross AE. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28058757" Prostate Health Index density improves detection of clinically significant prostate cancer. BJU Int. 2017 Jan 6. doi: 10.1111/bju.13762. [Epub ahead of print]PMID:28058757
Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, Solnes LB, Ross AE, Schaeffer EM, Bivalacqua TJ, Partin AW, Pienta KJ, Szabo Z, De Marzo AM, Pomper MG, Allaf ME. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28736318" PSMA-targeted 18F-DCFPyL PET/CT in the Preoperative Staging of Men with High-risk Prostate Cancer: Results of a Prospective Phase II Single-Center Study. J Urol. 2017 Jul 20. [Epub ahead of print]PMID: 28736318.
Ball MW, Ross AE, Ghabili K, Kim C, Jun C, Petrisor D, Pan L, Epstein JI, Macura KJ, Stoianovici DS, Allaf ME. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28735018" Safety and Feasibility of Direct MRI-Guided Transperineal Prostate Biopsy Using a Novel MRI-Safe Robotic Device. Urology. 2017 Jul 19. pii: S0090-4295(17)30744-6. doi: 10.1016/j.urology.2017.07.010. [Epub ahead of print] PMID: 28735018.
Druskin SC, Ward R, Purysko AS, Young A, Tosoian JJ, Ghabili K, Andreas D, Klein E, Ross AE, Macura KJ. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28709889" Dynamic Contrast Enhanced MRI Improves Classification of Prostate Lesions: A Study of Pathologic Outcomes on Targeted Prostate Biopsy. J Urol. 2017 Jul 11. [Epub ahead of print]
Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28662647" A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6. PMID: 28662647
Urbanucci A, Barfeld SJ, Kytl V, Itkonen HM, Coleman IM, Vodk D, Sjblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, Alshalalfa M, Davicioni E, Erho N, Lloyd P, Karnes RJ, Ross AE, Schaeffer EM, Vander Griend DJ, Knapp S, Corey E, Feng FY, Nelson PS, Saatcioglu F, Knudsen KE, Tammela TLJ, Sauter G, Schlomm T, Nykter M, Visakorpi T, Mills IG. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28591577" Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Rep. 2017 Jun 6;19(10):2045-2059. PMID:28591577.
Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, Kolisnik T, Margrave J, Yousefi K, Choeurng V, Davicioni E, Trock BJ, Kane CJ, Pollack A, Davis JW, Feng FY, Klein EA. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28528811" Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. Eur Urol. 2017 May 18.[Epub ahead of print] PMID: 28528811.
Review Articles [RA]
Musicki B, Ross AE, Champion HC, Burnett AL, Bivalacqua TJ. Posttranslational modification of constitutive nitric oxide synthase in the penis. J Androl 2009 Jul-Aug; 30(4): 352-62.
Ross AE, D'Amico AV, Freedland SJ. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26123120" Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer. Prostate Cancer Prostatic Dis. 2015 Jun 30.
Mouraviev V, Lee B, Patel V, Albala D, Johansen TE, Partin A, Ross A, Perera RJ. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26503110" Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer. Prostate Cancer Prostatic Dis. 2015 Oct 27.
Miyahira AK, Lang JM, Den RB, Garraway IP, Lotan TL, Ross AE, Stoyanova T, Cho SY, Simons JW, Pienta KJ, Soule HR. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26477609" Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2015 Oct 19.
Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis. 2016 May 3.
Tosoian JJ, Ross AE, Sokoll LJ, Partin AW, Pavlovich CP. HYPERLINK "http://www.ncbi.nlm.nih.gov/pubmed/26614026" Urinary Biomarkers for Prostate Cancer. Urol Clin North Am. 2016 Feb;43(1):17-38.
Ross AE. Multigene Testing in Localized Prostate Cancer. J Natl Compr Canc Netw. 2016 May; 14(5 Supl): 659-62.
Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes and treatment considerations. Nat Rev Urol 2016. Oct 11. Epub ahead of print
Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, Pienta KJ, Allaf ME, Haberkorn U, Pomper MG, Gorin MA, Rowe SP. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen targeted PET imaging. Eur J Nucl Med Mol Imaging. 2017 Aug 1. PMID: 28765998.
Loeb S, Ross AE. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28661898" Genomic testing for localized prostate cancer: where do we go from here? Curr Opin Urol. 2017 Sep;27(5):495-499. PMID:28661898
Case Reports [CR]
Gupta AD, Bandari J, Ross AE, Tufaro AP, Bivalacqua TJ. Management of primary squamous cell carcinoma at the mucocutaneous junction of an illeal conduit. Urology. 2011, Sept 9.
Rowe SP, Deville C, Paller C, Cho SY, Fishman EK, Pomper MG, Ross AE, Gorin MA. Uptake of 18F-DCFPyL in Pagets Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET studies. Tomography. 2015 Dec; 1(2): 81-84.
Rowe SP, Mana-Ay M, Javadi MS, Szabo Z, Leal JP, Pomper MG, Pienta KJ, Ross AE, Gorin MA. PSMA-Based Detection of Prostate Cnacer Bone lesions with 18F-DCFPyl PET/CT: A Sensitive Alternative to (99m)Tc-MDP Bone Scan and Na18F PET/CT? Clin Genitourin Cancer. 2016 Feb;14(1):e115-8. doi: 10.1016/j.clgc.2015.09.011. Epub 2015 Sep 30. No abstract available.
Tosoian JJ, Reyes DK, Gorin MA, Hortopan S, Partin AW, Pienta KJ, Ross AE, Schaeffer EM. A novel approach to performing bone marrow aspiration at the time of radical prostatectomy. Urol Case Rep. 2016 Mar 28; 6:45-6.
Andreas D, Tosoian J, Carter HB, Landis P, Wolf S, Glavaris S, Lotan T, Partin A, Schaeffer E, Sokoll L, Ross AE. Elevated Prostate Health Index (PHI) and Reclassification Biopsy during Active Surveillance of Prostate Cancer. Urol Case Rep. Accepted in Press.
Tosoian JJ, Gorin MA, Rowe SP, Andreas D, Szao Z, Pienta KJ, Pomper MG, Lotan TL, Ross AE. Correltation of PSMA-Targeted 18F-DCFPyl PET/CT Findings with immunohistochemical and Genomic Data in a Patient with Metastatic Neuroendocrine Prostate Cancer. Clin Genitourin Cancer. 2016. Sept 18. Epub ahead of print.
Alam R, Tosoian JJ, Okani O, Ross AE, Vuica-Ross M. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28083474" Metastatic Prostate Cancer Diagnosed by Bone Marrow Aspiration in an Elderly Man Not Undergoing PSA Screening. Urol Case Rep. 2017 Jan 5;11:7-8. doi: 10.1016/j.eucr.2016.12.010. eCollection 2017 Feb. PMID: 28083474
Rowe SP, Gorin MA, Chu LC, Pienta KJ, Pomper MG, Ross AE, Macura KJ. An Unusual case of Penile Prostate Cancer Uncovered by Multiparametric MRI Targetted 18F-DCFPyL-PET/CT. Clin Nucl Med. 2017 Aug 12. PMID: 28806262.
Gorin MA, Marashdeh W, Ross AE, Allaf ME, Pienta KJ, Pomper MG, Rowe SP. HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/28704341" Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi. Nucl Med Commun. 2017 Sep;38(9):795-798. PMID:28704341
Book Chapters, Monographs [BC]
Ross AE, Burnett AL. Anuria and oliguria. 5-Minute Urology Consult, 2nd Ed. 2009.
Ross AE, Burnett AL. Balanitis and balanoposthitis. 5-Minute Urology Consult, 2nd Ed. 2009.
Ross AE, Bivalacqua TJ. Bladder Cancer Superficial. Handbook of Urology. 2012
Ross AE, Bivalacqua TJ. Invasive Bladder Cancer/Urinary Diversion. Handbook of Urology. 2012
Ross AE, Stoianovici D, Allaf ME. MR-Guided Interventions of the Prostate. Advances in Image Urologic Surgery. 2014.
Ross AE, Rodriguez R. Development, Molecular Biology and Physiology of the Prostate, Wein: Campbell-Walsh Urology 11th Ed. 2016
Other Publications:
Review Series
Ross AE, Carter HB. A review of the AUA Guideline (2013) on Prostate Cancer Detection and New Approaches to Detection of Prostate Cancer. AUA Update Series 2014.
Ross AE, DAmico AV, Freedland S. Molecular Prognostic Tests for Prostate Cancer. UpToDate. 2014-7.
Editorials [ED]
Tosoian JJ, Tran PT, Ross AE. Concurrent Androgen Deprivation with Radiotherapy: A Cautionary Tale of Do As I Say, Not As I Do? Eur Urol. 2016 April 11. Epub Ahead of print.
Ludwig WW, Ross AE, Pierorazio PM. Local therapy for Gleason 9-10 Prostate Cancer: Looking to the Future. Eur Urol 2016.
Other Media [OM]
Petrylak D, Gleave M, Ross AE. For the Urologist, by the urologist: Essential Concepts in mCRPC. MedScape CME online course 2015.
Garcia, J, Morgans A, Ross AE, Saltzstein D, Concepcion RS. Debates Surrounding the Treatment of Prostate Cancer. OncLive Peer Exchange 2016.
FUNDED RESEARCH
DOD PRTA --W81XWH-13-1-0445 7/1/2013 - 6/30/2017 4.8 cal mos
$842,398
Congressionally Directed Medical Research Department of Defense
PC121446 - Description of MERTK as a Marker of Disease Aggressiveness and Regulator of Prostate Cancer Metastasis
Description of MERTK as a marker of disease aggressiveness and regulator of prostate cancer metastasis Role: PI
LDE225XUS13T (Clinical Trial) 05/22/14-05/21/17
Novartis Pharmaceuticals Corp
$418,802
A pharmacodynamics pre-surgical study of Hedgehog pathway inhibition with LDE225 in Men with high Risk localized prostate cancer.
The goal of the study is to determine the pharmacodynamics effects of LDE225 on resected prostate tissue from men undergoing radical prostatectomy for high-risk localized prostate cancer.
Role: Co-PI
MERCK (Clinical Trial) 12/01/2014 11/30/2017
$357,700
A Pilot Study of MK-3475 with Cryotherapy for Oligo-Metastatic Prostate Cancer
This project is a clinical trial studying the combination of MK-3475 with short term androgen ablation and cryotherapy for oligo-metastatic prostate cancer.
Role: PI
PROSTATE CANCER FOUNDATION 12/01/2015-12/01/2018
Prostate Cancer Foundation
$225,000
Effects of Local Therapy on the Systemic Anti-Tumor Response: Exploration of the Abscopal Effect in Mouse Models for Prostate Cancer
Role: PI
CA140917 09/30/15-09/29/17
US Department of Defense
$150,000
Enhancing Immune Checkpoint Inhibitor Therapy in Kidney Cancer
Role: Co-Investigator (PI: Dr. Hans Hammers)
Philanthropy: ~$75,000 per year in patient donations from 2014-present
Completed
Prostate Cancer Foundation 7/1/2013-8/31/2015
$660,000
Molecular and Clinical Investigations to Reduce the Morbidity of Prostate Cancer
Role: Co-Investigator (PI: Edward Schaeffer)
INTRAMURAL Funding
Patrick C. Walsh Prostate Cancer Research Fund 11/1/2015-11/1/2016
A Randomized Trial for the Use of Multi-Parametric MRI in Prostate Cancer Screening.
Patrick C. Walsh Prostate Cancer Research Fund
$100,000
Role: PI
Johns Hopkins Clinician Scientist Award 11/1/2012-11/1/2014
Description of MERTK as a Marker of Disease Aggressiveness and Regulator of Prostate Cancer Metastasis $75,000
Role: PI
CLINICAL ACTIVITIES
Clinical Focus Prostate Cancer
Certification
Medical, other state/government licensure
2010 present Maryland D71523
2017-present Texas R1629
Boards, other specialty certification
2014 present American Board of Urology
Clinical Program Building / Leadership
2015-2017: Director, Johns Hopkins Brady Urology Prostate Cancer Program
2015-2017 Co-Director, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Mutli-Disciplinary Prostate cancer Clinic
EDUCATIONAL ACTIVITIES
Teaching
Classroom instruction
2013-2017 Lecturer, Second Year Medical School Genitourinary Pathophysiology, Prostate Cancer (one yearly lecture)
2013-2015 Lecturer, Medical School Surgery Clerkship, Prinicples of Urology (quarterly lectures)
2013-2017 Lecturer, Radiation oncology residents, Prostate Cancer, a Urologists Perspective (once yearly lecture)
2016-2017 Lecturer, Urology Residents, Prostate Cancer State of the Art (one yearly lecture)
Clinical instruction
2012-2017 Urology resident education (clinic and OR)
CME instruction
2015 Lecturer, ASTRO, Synergy of Radiation and Immunotherapies in Prostate Cancer, lecture as part of CME course at ASTRO
2016 Organizer and Moderator Medscape Course From Urologist to Urologist, Castrate Resistant Prostate Cancer (online web content, CME course)
Workshops /seminars
2013-2016 NASPCC (National Alliance of State Prostate Cancer Coalitions) Annual conference Invited Lecturer (annual lecture on evolving technologies and practice in prostate cancer.
2014 Society of Urology Oncology Panelist, Molecular tools for Prostate Cancer Detection
2014 Kettering Medical Education Conference Invited Lecturer, Management of Localized Prostate Cancer
2014, 2016 Amtrak Alliance Urology Conference Invited Lecturer, Prostate cancer immunotherapy, Prostate cancer detection screening and diagnosis
2015 Prostate Health Education Network Annual Conference Invited Lecturer -- molecular basis of prostate cancer in African Americans
2015 UROTRACK Conference Invited Lecturer --Prostate Cancer Biomarkers
2015 ASTRO Education Course Lecturer (Immunotherapy in Prostate Cancer)
2015 Prostate Cancer Foundation Norway Invited Lecturer, Prostate Cancer Biomarkers and Management of Metastatic Prostate Cancer
2016 National Comprehensive Cancer Network (NCCN) annual meeting Invited Lecturer (Prostate Cancer Tissue Biomarkers)
2016 UROTRACK Conference Session leader and lecturer Prostate Cancer
2016 Prostate Cancer Academy Invited Lecturer, High Risk Prostate Cancer
2017 Future Directions Urology Symposium Invited Lecturer, Prostate Cancer Genomics
2017 Society of Urological Oncology Invited Lecturer, Prostate Cancer Genomics
Mentoring
Pre-doctoral Advisees /Mentees
2013-2015 Farzana Faisal, MD, mentored while medical student, shared publications Original Research 31, 33, 35, 36, 43, 45
2014-Present Stephanie Glavaris, B.S., technician, shared publications: Original Research 41, 49 and Case Report 5
2016-Present Darian Andreas, B.S., medical student, shared publication: Case Report 5
Post-doctoral Advisees /Mentees
2012-2015 Debashish Sundi, MD, urology resident and post-doctoral fellow, shared publications: Original research 24, 27, 28, 29, 31, 32, 33, 35, 36, 38, 44, 45
2014-2016 Benjamin Benzon MD, post-doctoral research fellowship, shared publications: Original research 44
2015-present Jeffrey Tosoian, MD MPh, urology resident and post-doctoral fellow, shared publications: Original research 38, 45, 49, 50, 51; Review 6, Case report 4, 5, Editorial 1
2015-present Zeyad Schwen, MD, urology resident: Original research 50
2015-present Kamyar Ghabili, MD, post-doctoral research fellowship
Educational Program Building / Leadership
2015-2017: Leader, organizer, frequent lecturer, Johns Hopkins Interdepartmental Prostate Cancer Meeting (thrice monthly meeting attended by urology, radiation oncology, medical oncology, pathology and associated research faculty and staff focusing on high risk and metastatic prostate cancer, prostate cancer biomarkers and novel treatment modalities)
RESEARCH ACTIVITIES
Research Focus
My research revolves around the better identification and treatment of aggressive prostate cancer. This includes basic research but primarily translational efforts and clinical trials (some examples below). I have also been a leader in the development and understanding of genomic tests for prostate cancer.
Investigator initiated trials translated from laboratory research of the Ross Laboratory
A pharmacodynamics pre-surgical study of Hedgehog pathway inhibition with LDE225 in Men with high Risk localized prostate cancer
A Pilot Study of MK-3475 with Cryotherapy for Oligo-Metastatic Prostate Cancer
Trials of novel/emerging technologies
A Randomized Trial for the Use of Multi-Parametric MRI in Prostate Cancer Screening
A Pilot Study of PET/PSMA in men with Biochemically Recurrent Prostate Cancer.
ORGANIZATIONAL ACTIVITIES
2012- 2017 Urology representative, Johns Hopkins Committee on Cancer
2013-2017 Urology representative, Patient Flow Meeting, Johns Hopkins
2014-2017 SKCCC Safety Monitoring Committee Member
2015-2017 Johns Hopkins Brady Urology Prostate Cancer Program Director. Organization of weekly prostate cancer informational and research strategy meetings. Interface with industry for the adoption of new technologies. Evaluations of prostate cancer care within Hopkins Urology. Evaluation and implementation of new technologies regarding prostate cancer within Johns Hopkins Urology
2015-2017 Co-Director, Johns Hopkins Multi-Disciplinary Prostate Cancer Clinic. Manage workflow through clinic and patient selection
EDITORIAL ACTIVITIES
Editorial Board appointments
2014-present Associate editor, Prostate Cancer Prostatic Diseases
2015-present Associate editor, Annals of Surgical Oncology
2016-present Associate editor, Urology
2016-present Editorial board, British Journal Urology International
2016-present Editorial Committee, Urology Practice
Journal peer review activities
2009-present British Journal of Urology International
2009-present Urology
2010-present Lasers in Surgery and Medicine
2011-present Journal of Theoretical Biology
2012-present Asian Journal of Urology
2012-present Cancer Epidemiology, Biomarkers and Prevention
2013-present Current Cancer Drug Targets
2013-present Prostate Cancer Prostatic Disease
2013-present Urologic Oncology
2013-present Journal of Clinical Oncology
2013-present Journal of the National Cancer Institute
2014-present International Journal of Radiation Oncology, Biology, Physics 2014-present
2015-present European Urology
2915-present Oncotarget
Advisory Committees, Review Groups/Study Sections
Grant Study Sections
2014 DOD PRTA Prostate Cancer Grant Reviewer
2015 DOD Prostate Cancer Health Disparity Grant Reviewer
Professional Societies
2006- Alpha Omega Alpha (AOA), member
2008- American Urologic Association, member
2013- American Society of Clinical Oncology, member
Conference Organizer
2015 Prostate Cancer Foundation Coffey-Holden National Meeting Organizer and Presenter, High Risk and Oligo-Metastatic Prostate cancer
2016- Prostate Cancer Foundation International Working Group on Molecular Imaging Organizer
OTHER RECOGNITION
Other Awards, Honors
1996 Junior Merck Index Award
1996 University of Maryland Senior Summer Scholarship
1996 Howard Hughes Medical Institute Undergraduate Research Fellowship
1997 Medical Scientist Training Program Fellowship
2005 Pathology Young Investigators Award for Excellence in Clinical Research
2006 Academy of Achievement Award
2006 Surgical Intern of the Year, Johns Hopkins Hospital, Department of Surgery
2007 Surgery Clerkship Teaching Award, Outstanding Junior Resident Teacher, Johns Hopkins
Hospital
2007 Johns Hopkins Bayview Medical Center Shining Star Award
2008 Johns Hopkins Bayview Medical Center Shining Star Award
2008 Johns Hopkins Hospital Catch A Shining Star Annual Award Winner
2009 Johns Hopkins Department of Medicine Osler Medical Housestaff Teaching Award
2010 Honorable Mention, Johns Hopkins University Fifth Annual Prostate Research Day Defining the Molecular Basis of High Risk, Lethal Prostate Cancer
2012 Honorable Mention, Johns Hopkins University Seventh Annual Prostate Research Day
Development of simple genomic predictors to distinguish indolent and lethal prostate cancer
2012 First Prize, Paper Presentation, Baltimore-Washington-West Virginia Urology Resident Day
2013 Honorable Mention, Johns Hopkins University Eight Annual Prostate Research Day
A genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post prostatectomy
2017 Best fundamental research paper, EAU
PAGE \* MERGEFORMAT 9
! " * 2 3 H I b c d f Źũ~rbSA "hz! 5B*
CJ OJ QJ aJ ph p hl@ h4F CJ OJ QJ aJ hg h4F 5CJ OJ QJ aJ hY CJ OJ QJ aJ hg h! CJ OJ QJ aJ h! CJ OJ QJ aJ h! h4F 5CJ OJ QJ aJ h! hI 5CJ OJ QJ aJ h CJ OJ QJ aJ hg h4F CJ OJ QJ aJ h4F OJ QJ j h4F Uh4F j h4F CJ OJ QJ Uhg CJ OJ QJ " 3 I c d e f = u p^p`gdG gdG gd}F` $a$ $a$gdg
)
p@ P !$ gdg ; < ʺnYI9I9I9 hG B*CJ OJ QJ aJ ph hI B*CJ OJ QJ aJ ph (h3
h3
6B*CJ OJ QJ aJ ph "h3
6B*CJ OJ QJ aJ ph (hs=+ h3
5B*
CJ OJ QJ aJ ph p "h3
5B*
CJ OJ QJ aJ ph p %hs=+ h}F` B*CJ OJ QJ aJ ph hz! B*CJ OJ QJ aJ ph "h" 6B*CJ OJ QJ aJ ph "hg 5B*
CJ OJ QJ aJ ph p "h}F` 5B*
CJ OJ QJ aJ ph p < = t u
%
&
(
-
.
/
1
^
( 5 6 ̼qbVbVbVbqbVbVbVbJbqb hG CJ OJ QJ aJ h[ CJ OJ QJ aJ hZu hG CJ OJ QJ aJ hZu hG >*CJ OJ QJ aJ %hs=+ h4F B*CJ OJ QJ aJ ph (hs=+ h4F 5B*
CJ OJ QJ aJ ph p %hl@ h4F B*CJ OJ QJ aJ ph hHR B*CJ OJ QJ aJ ph h4F B*CJ OJ QJ aJ ph hG B*CJ OJ QJ aJ ph %hs=+ h4F B*CJ OJ QJ aJ ph
&
J
( 6
"
D
F
G
`
gd p^p`gdG ^`gdG gdG 6 8 = ? ! # ( ) . D
E
F
G
^
_
;婖nY (hs=+ h4F 5B*CJ OJ QJ aJ ph (hs=+ h4F 5B*
CJ OJ QJ aJ ph p %hl@ h4F B*CJ OJ QJ aJ ph %hs=+ h4F B*CJ OJ QJ aJ ph (hs=+ h4F 6B*CJ OJ QJ aJ ph hZu hY CJ OJ QJ aJ hY CJ OJ QJ aJ hG CJ OJ QJ aJ hZu hG CJ OJ QJ aJ h[ CJ OJ QJ aJ _
`
b
g
j
n
# % ) Źԭԉ}hXHX h! 5B*CJ OJ QJ ph hoe 5B*CJ OJ QJ ph (hl@ h& 5B*CJ OJ QJ aJ ph h! CJ OJ QJ aJ hq CJ OJ QJ aJ h3
CJ OJ QJ aJ h CJ OJ QJ aJ h*7 CJ OJ QJ aJ hG CJ OJ QJ aJ hZu hG CJ OJ QJ aJ hI CJ OJ QJ aJ h[ CJ OJ QJ aJ %hz! hz! B*CJ OJ QJ aJ ph & ' | <
& F gdT
& F gdT
& F gd" ^gdT
& F gd3 `^``gd7j gd" gdI
$ % & ' 0 2 : ̷rbO:O* hT B*CJ OJ QJ aJ ph (h" hY 5B*CJ OJ QJ aJ ph %h" hY B*CJ OJ QJ aJ ph hoe B*CJ OJ QJ aJ ph !h" 6B*CJ OJ QJ ]ph hY B*CJ OJ QJ ph %h7j h7j B*CJ OJ QJ aJ ph %h7j h7j B*
CJ OJ QJ aJ ph p (hl@ h& 5B*
CJ OJ QJ aJ ph p $h~X h& 6B*CJ OJ QJ php0 !h~X h4F B*CJ OJ QJ php0 h4F 5B*CJ OJ QJ ph
{ | - 4 Ǵǡq_N?ǡǡ hT hY CJ OJ QJ aJ h" hY 0JA CJ OJ QJ aJ #h" hY 0JA 5CJ OJ QJ aJ hT hT 0JA CJ OJ QJ aJ h" hY 5CJ OJ QJ aJ h" hY CJ OJ QJ aJ %hT hT B*CJ OJ QJ aJ ph %hT hY B*CJ OJ QJ aJ ph %h" hY B*CJ OJ QJ aJ ph (h" hY 5B*CJ OJ QJ aJ ph h" B*CJ OJ QJ aJ ph s . s & g " C
& F [$ \$ gdG
& F gd" <
& F gd" ?
& F -D M
gdT ?
& F -D M
gd"
& F gdT
& F gd3 @
& F -D M
[$ \$ gd3 >
& F gdT r s } - . 5 r s $ % 5 < xf"hT hY 5CJ OJ QJ \aJ h" hY 0J5 CJ OJ QJ aJ h" hT CJ OJ QJ aJ h" hT 5CJ OJ QJ aJ hT hY CJ OJ QJ ^J aJ hT hY CJ OJ QJ aJ hY CJ OJ QJ aJ h" CJ OJ QJ aJ h" hY CJ OJ QJ aJ h" hY 5CJ OJ QJ aJ ( f g ! ! " " " (" /" " " " " " # # # # # # $ $ % % ?& @& G& & ҲҦÇxh hU$ hY >*CJ OJ QJ aJ h" hT CJ OJ QJ aJ hG hY >*CJ OJ QJ aJ hG hG CJ OJ QJ aJ hG CJ OJ QJ aJ h" hY 0JA CJ OJ QJ aJ hT hG CJ OJ QJ aJ h" hY CJ OJ QJ aJ h" hY 5CJ OJ QJ aJ hT hY CJ OJ QJ aJ (" " " # $ @& ' `( i) * + + , - . s/ '1
& F -D 9D M
gdT
& F
! gd3
& F
! gd"
& F
! gdT B
& F [$ \$ gdT C [$ \$ ^gdG & &
' ' ' ' ' Q' X' 5( I( L( ^( _( `( h( ( ( h) i) r) y) * * * * * + + + D+ K+ + + + , , , , , , - - - . . r. . . . ťʼnʼnʼn} hZ CJ OJ QJ aJ hZ hY >*CJ OJ QJ aJ hY CJ OJ QJ aJ hU$ hY >*CJ OJ QJ aJ hx_ hY >*CJ OJ QJ aJ hT hY CJ OJ QJ aJ hU$ CJ OJ QJ aJ h" hY CJ OJ QJ aJ h" hY 5CJ OJ QJ aJ 1. . . . r/ s/ / / 0 :0 ;0 t0 u0 0 0 %1 wX4w Fj hS hY 0J; >* B* CJ OJ QJ UaJ eh @ph r @ =hS hY 0J; >* B* CJ OJ QJ aJ eh @ph r @ hS hY CJ OJ QJ aJ %j hS hY CJ OJ QJ UaJ (h" hY 5B*CJ OJ QJ aJ ph %h" hY B*CJ OJ QJ aJ ph hT hS CJ OJ QJ aJ h" hY 5CJ OJ QJ aJ h" hY CJ OJ QJ aJ hS hY >*CJ OJ QJ aJ %1 &1 '1 .1 `1 s1 v2 w2 2 2 2 2 2 2 3 3 U3 V3 t3 óäÕc? Fj hU hY 0J; >* B* CJ OJ QJ UaJ eh @ph r @ =hU hY 0J; >* B* CJ OJ QJ aJ eh @ph r @ %j hU hY CJ OJ QJ UaJ hU hY CJ OJ QJ aJ hN5 hY CJ OJ QJ aJ hx_ hY >*CJ OJ QJ aJ h" hY CJ OJ QJ aJ h" hY 5CJ OJ QJ aJ hS hS CJ OJ QJ aJ hS hT CJ OJ QJ aJ '1 w2 3 L5 M5 6 6 W8 9 ; u ] B
& F -D M
[$ \$ gd3 E
& F -D M
[$ \$ gd3
! gd"
& F
! gd3 -D 9D M
^gd C
& F -D 9D M
gd C
& F -D 9D M
gdU
& F d -D 9D M
[$gdN5 t3 3 3 3 4 4 B4 C4 |4 }4 5 5 L5 M5 T5 5 ǷǤǤaRB3 h" hY CJ OJ QJ aJ h" hY 5CJ OJ QJ aJ h C h C CJ OJ QJ aJ Fj h C hY 0J; >* B* CJ OJ QJ UaJ eh @ph r @ =h C hY 0J; >* B* CJ OJ QJ aJ eh @ph r @ %j h C hY CJ OJ QJ UaJ h C hY 5CJ OJ QJ aJ h C hY CJ OJ QJ aJ hU CJ OJ QJ aJ hU hY CJ OJ QJ aJ hU hN5 CJ OJ QJ aJ 5 5 5 5 6 6 6 7 .7 /7 67 7 7 7 7 )8 *8 =8 wddM2 5j hh4} hY 0J; >* B* CJ OJ QJ UaJ ph ,hh4} hY 0J; >* B* CJ OJ QJ aJ ph %j hh4} hY CJ OJ QJ UaJ "hh4} hY 5CJ OJ QJ \aJ hh4} hY 0JD CJ OJ QJ aJ hx_ hY >*CJ OJ QJ aJ hh4} hY CJ OJ QJ aJ -h" hY CJ OJ QJ aJ fH q
h C hY >*CJ OJ QJ aJ h" hY CJ OJ QJ aJ hh4} hY >*CJ OJ QJ aJ =8 V8 W8 y8 8 8 8 8 9 9 9 >9 ?9 9 ѸџvcvcD =hh4} hY 0J; >* B* CJ OJ QJ aJ fH ph q
%j hh4} hY CJ OJ QJ UaJ hh4} hY CJ OJ QJ aJ 3hh4} hY 5CJ OJ QJ \aJ fH q
1hh4} hY 0JD CJ OJ QJ aJ fH q
0hx_ hY >*CJ OJ QJ aJ fH q
-hh4} hY CJ OJ QJ aJ fH q
hY CJ OJ QJ aJ hBb CJ OJ QJ aJ
9 9 9 9 9 9 9 9 9 : &: .: : : : ܽyjZjZjJj:j hh4} hY 5CJ OJ QJ aJ hx_ hY >*CJ OJ QJ aJ hZ hY >*CJ OJ QJ aJ hh4} hY CJ OJ QJ aJ 'hY CJ OJ QJ aJ fH q
-hh4} hY CJ OJ QJ aJ fH q
1hh4} hY 0JA CJ OJ QJ aJ fH q
=hh4} hY 0J; >* B* CJ OJ QJ aJ fH ph q
Fj hh4} hY 0J; >* B* CJ OJ QJ UaJ fH ph q
: : 8; 9; ; ; ; ; < < #< =< F< < < < < A= B= C= K= W= X= = = = = ƫݚݎ~nƫ]ݎnQ hom CJ OJ QJ aJ hh4} hZ 0JA CJ OJ QJ aJ hh4} hY 5CJ OJ QJ aJ hZ hY >*CJ OJ QJ aJ hY CJ OJ QJ aJ hh4} hY 0JA CJ OJ QJ aJ 5j hh4} hY 0J; >* B* CJ OJ QJ UaJ ph ,hh4} hY 0J; >* B* CJ OJ QJ aJ ph hh4} hY CJ OJ QJ aJ %j hh4} hY CJ OJ QJ UaJ ; < X= > ? sA B D yE F G v ^ ^ ^ G
& F -D M
[$ \$ gdT B
& F -D M
[$ \$ gd" G
& F -D M
[$ \$ gdom
& F -D M
gd3 B
& F -D M
[$ \$ gdom B
& F -D M
[$ \$ gdZ C -D M
[$ \$ ^gdZ
= = = = j> k> l> v> > > > > > '? (? a? b? ? ? ? ? ? ? ? 1@ 5@ ƫݚݎm]MAm hom CJ OJ QJ aJ hom hY CJ OJ QJ \aJ hh4} hY 5CJ OJ QJ aJ "hh4} hY 5CJ OJ QJ \aJ hh4} hY CJ OJ QJ aJ hY CJ OJ QJ aJ hom hY 0JA CJ OJ QJ aJ 5j hom hY 0J; >* B* CJ OJ QJ UaJ ph ,hom hY 0J; >* B* CJ OJ QJ aJ ph hom hY CJ OJ QJ aJ %j hom hY CJ OJ QJ UaJ 5@ 7@ w@ x@ @ @ FA NA VA WA rA sA A A A A B B B B RB SB B B B B B B C PC WC ZC [C ͊o^Rhom CJ OJ QJ aJ hh4} hY 0JA CJ OJ QJ aJ 5j hh4} hY 0J; >* B* CJ OJ QJ UaJ ph ,hh4} hY 0J; >* B* CJ OJ QJ aJ ph hx_ hY >*CJ OJ QJ aJ hY CJ OJ QJ aJ hh4} hY CJ OJ QJ \aJ %j hh4} hY CJ OJ QJ UaJ hh4} hY CJ OJ QJ aJ hh4} hY 5CJ OJ QJ aJ [C C C C C C C D D D 'D 0D xE yE ǬxiYJ:J+ hT hQ CJ OJ QJ aJ hx_ h`v >*CJ OJ QJ aJ hh4} h`v CJ OJ QJ aJ hh4} h`v 5CJ OJ QJ aJ hT h`v CJ OJ QJ aJ hom hY CJ OJ QJ aJ hom hY 0JA CJ OJ QJ aJ &hom 0J; >* B* CJ OJ QJ aJ ph 5j hh4} hY 0J; >* B* CJ OJ QJ UaJ ph ,hh4} hY 0J; >* B* CJ OJ QJ aJ ph %j hh4} hY CJ OJ QJ UaJ hh4} hY CJ OJ QJ aJ
yE E E vF F F F F G G G G 1H :H TH [H H H I !I "I I I
J J ѾѩіссѩѾсkѩV )hT hQ B*CJ OJ QJ ^J aJ ph +hn* hQ 6>*B*CJ OJ QJ aJ ph (hn* hQ >*B*CJ OJ QJ aJ ph %hn* hT B*CJ OJ QJ aJ ph (hn* hQ 5B*CJ OJ QJ aJ ph %hT hQ B*CJ OJ QJ aJ ph %hn* hQ B*CJ OJ QJ aJ ph h9 N hQ 5CJ OJ QJ aJ hQ CJ OJ QJ aJ G H J AK BK ~L N N P Q S S T U ~ ~ B
& F -D M
[$ \$ gdT C -D M
[$ \$ ^gdT B
& F -D M
[$ \$ gd~ G
& F -D M
[$ \$ gd< V J ^ gdoe G
& F -D M
[$ \$ gdT
J J /J 9J DJ KJ nJ uJ @K AK }K K L qL }L ~L L L L L L `M hM M N N N N )N 4N ԽԨԽԓ~ԽԓgP ,hn* h< V >*B*CJ OJ QJ ^J aJ ph ,hT h< V >*B*CJ OJ QJ ^J aJ ph )hT hQ B*CJ OJ QJ ^J aJ ph )hn* h< V B*CJ OJ QJ ^J aJ ph )hT hoe B*CJ OJ QJ ^J aJ ph ,hn* hQ 5B*CJ OJ QJ ^J aJ ph )hn* hQ B*CJ OJ QJ ^J aJ ph ,hn* hQ >*B*CJ OJ QJ ^J aJ ph 4N ;N N N N N O O P P P ԽhIh6# %hn* hQ B*CJ OJ QJ aJ ph %hn* h< V B*CJ OJ QJ aJ ph =hn* h< V 5B*CJ OJ QJ ^J aJ fH ph q
:hn* h< V B*CJ OJ QJ ^J aJ fH ph q
>hn* h< V 0JL B*CJ OJ QJ ^J aJ fH ph q
,hn* hQ >*B*CJ OJ QJ ^J aJ ph ,hn* hT >*B*CJ OJ QJ ^J aJ ph )hn* h< V B*CJ OJ QJ ^J aJ ph ,hn* h< V 5B*CJ OJ QJ ^J aJ ph
P P P P Q Q RR SR WR XR ZR Ħđ|eM4 ,h~ h~ 5B*CJ OJ QJ ^J aJ ph 0h~ h~ 0JD 5B*CJ OJ QJ ^J aJ ph /h~ h~ 5B*CJ OJ QJ \^J aJ ph -h~ h~ 0JD B*CJ OJ QJ ^J aJ ph )h~ h~ B*CJ OJ QJ ^J aJ ph )hT h~ B*CJ OJ QJ ^J aJ ph ;h~ 0JL 5B*CJ OJ QJ ^J aJ fH ph q
8h~ 0JL B*CJ OJ QJ ^J aJ fH ph q
;h~ 0JL >*B*CJ OJ QJ ^J aJ fH ph q
ZR S S S S S S S S AT KT T T 꾧v_H6 #h * B*CJ OJ QJ ^J aJ ph -h * h * 0JA B*CJ OJ QJ ^J aJ ph ,h * h * 5B*CJ OJ QJ ^J aJ ph 0h * h * 0JD 5B*CJ OJ QJ ^J aJ ph /h * h * 5B*CJ OJ QJ \^J aJ ph -h * h * 0JD B*CJ OJ QJ ^J aJ ph )h * h * B*CJ OJ QJ ^J aJ ph -h~ h~ 0JA B*CJ OJ QJ ^J aJ ph )h~ h~ B*CJ OJ QJ ^J aJ ph T T U U U U V V V W W W RW SW W W W W W !X "X جukVVDVk6 h;e CJ OJ QJ ^J aJ #h8V9 h;e CJ OJ QJ \^J aJ )j h8V9 h;e CJ OJ QJ U^J aJ h;e OJ QJ ^J #h8V9 h;e 5CJ OJ QJ ^J aJ &h8V9 h;e 5CJ OJ QJ \^J aJ h8V9 h;e CJ OJ QJ ^J aJ )hT h;e B*CJ OJ QJ ^J aJ ph ,h * h * 5B*CJ OJ QJ ^J aJ ph #h * B*CJ OJ QJ ^J aJ ph )hT h * B*CJ OJ QJ ^J aJ ph "X /X 0X X X X X X X 8Y 9Y tY |Y Y Y Y Y Y Z Z aZ eZ hZ iZ kZ lZ Z Z [ [ ^[ _[ a[ [ [ [ [ 1\ 5\ 8\ Q\ S\ T\ \ \ ]
] ] ] ] ] ] ] ] ʸﮙʸﮙʸﮙ #h8V9 h;e CJ OJ QJ \^J aJ )j h8V9 h;e CJ OJ QJ U^J aJ h;e OJ QJ ^J #h8V9 h;e 5CJ OJ QJ ^J aJ &h8V9 h;e 5CJ OJ QJ \^J aJ hT h;e CJ OJ QJ ^J aJ h8V9 h;e CJ OJ QJ ^J aJ 5U 0X Z [ ] +_ ` ` b d &g h ,k 2m n p Ds t v
& F d d [$\$gdT
& F -D M
gdu
-D M
gd;e
& F -D M
gdT
& F -D M
gd;e ] ]
^ ^ ^ J^ K^ S^ ^ ^ ^ ^ ^ _ _ )_ *_ +_ _ _ _ _ _ _ _ _ ` ` p` q` s` {` ` ` ` ` ` ` ` ` ga ia ja a a a a #b ҽܽܫܽܝxҽܽܫܽҫ܌xҽܽܫ &h8V9 h;e 5CJ OJ QJ \^J aJ hT h;e CJ OJ QJ ^J aJ h;e CJ OJ QJ ^J aJ #h8V9 h;e CJ OJ QJ \^J aJ )j h8V9 h;e CJ OJ QJ U^J aJ h;e OJ QJ ^J h8V9 h;e CJ OJ QJ ^J aJ #h8V9 h;e 5CJ OJ QJ ^J aJ /#b $b &b b b b b b b b b b c c c c c d d d d d d d d d d *e .e 1e e e e e e ]f ef f f f g g %g &g ϮϮ|n h;e CJ OJ QJ ^J aJ #h8V9 h;e CJ OJ QJ \^J aJ hu CJ OJ QJ ^J aJ #h8V9 h;e 5CJ OJ QJ ^J aJ &h8V9 h;e 5CJ OJ QJ \^J aJ hT h;e OJ QJ ^J h8V9 h;e CJ OJ QJ ^J aJ h;e OJ QJ ^J )j h8V9 h;e CJ OJ QJ U^J aJ +&g g g g g g g h h /h 7h h h h h h h h i i i !j #j $j ^j _j j j j j j k k !k #k +k ,k k k k l l l Ol Pl l l l l l m "m 'm )m 1m ￪謹￪謹￪謹 hu h;e OJ QJ ^J #h8V9 h;e CJ OJ QJ \^J aJ )j h8V9 h;e CJ OJ QJ U^J aJ h;e OJ QJ ^J #h8V9 h;e 5CJ OJ QJ ^J aJ &h8V9 h;e 5CJ OJ QJ \^J aJ h8V9 h;e CJ OJ QJ ^J aJ 61m 2m m m m m m m n n Xn `n qn rn tn n n n n Zo ^o ao bo do eo o o o o o o
p p
p p ͻᱜᜱyͻllZ #hu h;e CJ OJ QJ \^J aJ hu h;e OJ QJ ^J hT hu CJ OJ QJ ^J aJ #h8V9 h;e CJ OJ QJ \^J aJ )j h8V9 h;e CJ OJ QJ U^J aJ h;e OJ QJ ^J #h8V9 h;e 5CJ OJ QJ ^J aJ &h8V9 h;e 5CJ OJ QJ \^J aJ h8V9 h;e CJ OJ QJ ^J aJ h;e CJ OJ QJ ^J aJ "p *p pp qp vp xp p p kq oq rq r r r >r ?r wr r r r r 2s 4s 9s ;s Cs ެސ{j{jXj{KjKjKj h) h;e OJ QJ ^J #h) h;e CJ OJ QJ \^J aJ h) h;e CJ OJ QJ ^J aJ )j h) h;e CJ OJ QJ U^J aJ h;e OJ QJ ^J #h8V9 h;e 5CJ OJ QJ ^J aJ &h8V9 h;e 5CJ OJ QJ \^J aJ hT h;e CJ OJ QJ ^J aJ hu h;e OJ QJ ^J h8V9 h;e CJ OJ QJ ^J aJ hu h;e CJ OJ QJ ^J aJ Cs Ds s s s s s s t t t Zt bt jt kt mt t t u u u lu ʸޫޖބޖsdRBd h) hQ 5CJ OJ QJ aJ "h) hQ 5CJ OJ QJ \aJ h) hQ CJ OJ QJ aJ hT hQ CJ OJ QJ ^J aJ #h) h;e CJ OJ QJ \^J aJ )j h) h;e CJ OJ QJ U^J aJ h) h;e OJ QJ ^J #h) h;e 5CJ OJ QJ ^J aJ &h) h;e 5CJ OJ QJ \^J aJ h) h;e CJ OJ QJ ^J aJ h) hu CJ OJ QJ ^J aJ lu mu u u v
v Lv Mv v v v v v v v 5w 6w pw xw w w 'x {x x ݾzzjz[I "h) hD 5CJ OJ QJ \aJ h) hD CJ OJ QJ aJ h) hP# CJ OJ QJ \aJ %j h) hP# CJ OJ QJ UaJ h) hP# 5CJ OJ QJ aJ "h) hP# 5CJ OJ QJ \aJ h) hP# CJ OJ QJ aJ hT hP# CJ OJ QJ aJ h) hQ CJ OJ QJ \aJ h) hQ CJ OJ QJ aJ %j h) hQ CJ OJ QJ UaJ v 'x ~y d{ } ǀ Ȁ x ` B -D M
[$ \$ ^gdt
& F -D M
] gd8 -D M
] ^gdt
& F gdt gd gdY
& F d d [$\$gd)
& F d d [$\$gdX
& F d d [$\$gdc
& F d d [$\$gdD
& F d d [$\$gdP# x x x x x x y y @y Hy Py Qy ~y y y y Rz Sz z z z z
{ { d{ C| G| J| ଚwwwhVF hX hX 5CJ OJ QJ aJ "hX hX 5CJ OJ QJ \aJ hX hX CJ OJ QJ aJ %j h) hc CJ OJ QJ UaJ h) hc 5CJ OJ QJ aJ "h) hc 5CJ OJ QJ \aJ h) hc CJ OJ QJ aJ "h) hD 5CJ OJ QJ \aJ %j h) hD CJ OJ QJ UaJ h) hD CJ OJ QJ aJ h) hD 5CJ OJ QJ aJ J| | | +} ,} } } } } } } } } } ~ ~ X ` yyyfVG hY ht CJ OJ QJ aJ h B*
CJ OJ QJ aJ ph p %hY hY B*CJ OJ QJ aJ ph %j h) h) CJ OJ QJ UaJ h) h) 5CJ OJ QJ aJ "h) h) 5CJ OJ QJ \aJ h) h) CJ OJ QJ aJ h) hX CJ OJ QJ aJ "hX hX 5CJ OJ QJ \aJ %j hX hX CJ OJ QJ UaJ hX hX CJ OJ QJ aJ ! ƀ ǀ Ȁ π & ' iN=1 h8 CJ OJ QJ aJ hh4} h8 0JA CJ OJ QJ aJ 5j hh4} h8 0J; >* B* CJ OJ QJ UaJ ph ,hh4} h8 0J; >* B* CJ OJ QJ aJ ph %j hh4} h8 CJ OJ QJ UaJ ht CJ OJ QJ aJ hh4} h8 CJ OJ QJ aJ "hh4} h8 5CJ OJ QJ \aJ ht ht CJ OJ QJ aJ hY ht 0JA CJ OJ QJ aJ hY ht CJ OJ QJ aJ hY ht 5CJ OJ QJ aJ E F Ƃ ނ ߂ S T ϼϼϬϼϬϠϠnnW ,ht h\ 0J; >* B* CJ OJ QJ aJ ph %j ht h\ CJ OJ QJ UaJ ht h\ 5CJ OJ QJ aJ ht h\ CJ OJ QJ aJ ht CJ OJ QJ aJ ht ht CJ OJ QJ \aJ %j ht ht CJ OJ QJ UaJ ht ht CJ OJ QJ aJ ht ht 5CJ OJ QJ aJ "ht ht 5CJ OJ QJ \aJ ߂ 8 ; . / l m A B u D E X gd#dO
& F d d [$\$gd)
& F d d [$\$gdX J gd% J gd< V
& F gdl J gdl
& F gdt gdt B
& F -D M
[$ \$ gd]M J gdt
& F -D M
gdt ( 8 : ; D L w ~
- . / ; ͼo_SSFS7 ht hom CJ OJ QJ aJ ht 6CJ OJ QJ aJ ht CJ OJ QJ aJ hv| hv| 5CJ OJ QJ aJ hv| hv| >*CJ OJ QJ aJ hv| hv| CJ OJ QJ aJ h" h" 6CJ OJ QJ aJ ht h" CJ OJ QJ aJ ht h\ CJ OJ QJ aJ ht h\ 0JA CJ OJ QJ aJ ,ht h\ 0J; >* B* CJ OJ QJ aJ ph 5j ht h\ 0J; >* B* CJ OJ QJ UaJ ph ; ? B h i
ʅ ˅ k l m ϼϼϬϼϜvfYL? h< V 5CJ OJ QJ aJ h< V >*CJ OJ QJ aJ h< V 6CJ OJ QJ aJ h< V hl 6CJ OJ QJ aJ hl CJ OJ QJ aJ hl 5CJ OJ QJ aJ hl 6CJ OJ QJ aJ hl hom 6CJ OJ QJ aJ ht hom CJ OJ QJ \aJ %j ht hom CJ OJ QJ UaJ ht hom CJ OJ QJ aJ ht hom 5CJ OJ QJ aJ "ht hom 5CJ OJ QJ \aJ @ A B ˇ t } È C D ȶȚyiVVyVG h) h% CJ OJ QJ aJ %j hX hX CJ OJ QJ UaJ hX hX 5CJ OJ QJ aJ "hX hX 5CJ OJ QJ \aJ hX hX CJ OJ QJ aJ h% CJ OJ QJ aJ h86B h% 5CJ OJ QJ aJ "h86B h% 5CJ OJ QJ \aJ h86B h% CJ OJ QJ aJ h% 6CJ OJ QJ aJ h% h< V 6CJ OJ QJ aJ h< V CJ OJ QJ aJ D E W X Y n u K R T \ M T a ̾xj[L*CJ OJ QJ h` h5% 5CJ OJ QJ h` h5% CJ OJ QJ h` CJ OJ QJ aJ h" h" 5CJ OJ QJ aJ h" h" CJ OJ QJ aJ hY B*
CJ OJ QJ ph p h#dO B*
CJ OJ QJ ph p !hs=+ h#dO B*
CJ OJ QJ ph p (h2d hv| 6B*
CJ OJ QJ aJ ph p X Y
l m I O Ր x -D M
^gd%
& F -D M
gdu G
& F d -D M
gd` J gd` G
& F d -D M
[$ \$ gd` G d -D M
[$ \$ ^gd` ^gd`
& F gd` gd#dO
a k l m w I J R ] _ h p z { | ) O e ȻȜȜȫȜȜȜrȜȜe h< V >*CJ OJ QJ aJ h` 5CJ OJ QJ aJ hy! >*CJ OJ QJ aJ h` h` 5CJ OJ QJ aJ h` h` CJ OJ QJ aJ h` h` >*CJ OJ QJ aJ h` >*CJ OJ QJ aJ h` CJ OJ QJ aJ hY hU CJ OJ QJ aJ hY hU 0JA CJ OJ QJ aJ hU CJ OJ QJ aJ $e n w i j l Đ Ɛ ː ̐ Ԑ Ր ɵɑɇrrɑrɇɇdVHh! CJ OJ QJ ^J aJ h% CJ OJ QJ ^J aJ hu CJ OJ QJ ^J aJ )j h8V9 hu CJ OJ QJ U^J aJ hu OJ QJ ^J #h8V9 hu CJ OJ QJ \^J aJ #h8V9 hu 5CJ OJ QJ ^J aJ &h8V9 hu 5CJ OJ QJ \^J aJ h8V9 hu CJ OJ QJ ^J aJ h< V 5CJ OJ QJ aJ h< V >*CJ OJ QJ aJ h< V CJ OJ QJ aJ ʑ Α 8 9 G O ߒ H °°}jZJ; h~ h~ CJ OJ QJ aJ h~ h~ 5CJ OJ QJ aJ h#dO B*
CJ OJ QJ aJ ph p %hK% h#dO B*
CJ OJ QJ aJ ph p !hs=+ hY B*
CJ OJ QJ ph p hD hu CJ OJ QJ aJ %j hD hD CJ OJ QJ UaJ "hD hD 5CJ OJ QJ \aJ hD hD CJ OJ QJ aJ hD h! CJ OJ QJ ^J aJ h! CJ OJ QJ ^J aJ h! 5CJ OJ QJ ^J aJ ߒ U V h i d e f g | ~ gd J gdT J gd~ ^gd~
& F gd~ gd#dO G d -D M
^gdu
& F d d [$\$gdD H J T U V ] g h i p X Z c d e f g { | ԷԷԷԷԫyf %h h B*
CJ OJ QJ aJ ph p h $ 5B*
CJ OJ QJ ph p %h h B*
CJ OJ QJ aJ ph p h~ hT CJ OJ QJ aJ hT CJ OJ QJ aJ h~ 5CJ OJ QJ aJ h~ h~ 5CJ OJ QJ aJ h~ CJ OJ QJ aJ h~ h~ CJ OJ QJ aJ h~ h~ CJ H*OJ QJ aJ | ~ 1 < t нvjYK>0> h~ h`v >*CJ OJ QJ h~ h`v CJ OJ QJ h4F B*
CJ OJ QJ ph p !hs=+ h4F B*
CJ OJ QJ ph p h=C CJ OJ QJ aJ h{: h{: 5CJ OJ QJ aJ h{: h{: CJ OJ QJ aJ %h{: h{: B*CJ OJ QJ aJ ph (h{: h{: 5B*CJ OJ QJ aJ ph %h{: h{: B*
CJ OJ QJ aJ ph p h~ B*
CJ OJ QJ ph p h{: B*
CJ OJ QJ ph p %h7j h4F B*
CJ OJ QJ aJ ph p 2 3 _ ۗ ܗ t W ` gd r
! gd r
& F gd{: gd&
& F gdl
& F gd~ J gd{: m$ J
& F gd{: m$ ǖ ^ _ h j q ڗ ۗ ܗ
źťvhZM?2 h~ h{: CJ OJ QJ hQ h{: 5CJ OJ QJ hQ h{: CJ OJ QJ h{: B*
CJ OJ QJ ph p h B*
CJ OJ QJ ph p hK% B*
CJ OJ QJ ph p !hs=+ h4F B*
CJ OJ QJ ph p h~ B*
CJ OJ QJ aJ ph p )hl hl B*CJ OJ QJ ^J aJ phWWW hl 5CJ OJ QJ hl CJ OJ QJ hl >*CJ OJ QJ h~ CJ OJ QJ h~ h`v CJ OJ QJ h~ h`v 5CJ OJ QJ
m r t
3 W ` ՚ Ƹl\M\M\M\=\M hN1 h r CJ OJ QJ \aJ hN1 h r CJ OJ QJ aJ hN1 h r 5CJ OJ QJ aJ %hN1 h, B*CJ OJ QJ aJ ph "h4F 6B*CJ OJ QJ aJ ph "h=C 5B*CJ OJ QJ aJ ph (hN1 h4F 5B*CJ OJ QJ aJ ph h B*
CJ OJ QJ ph p h{: B*
CJ OJ QJ ph p h~ hQ CJ OJ QJ hQ 5CJ OJ QJ hQ CJ OJ QJ h{: CJ OJ QJ ֚ ߚ a * + _ h T ^ _ : D E
1$ 7$ 8$ H$ gd r
K
! gd r $H$ a$gd r
! gd r
gd r $
! H$ a$gd r gd r ՚ ֚ ߚ a + D ] h ] ^ z : E M a z : < F ` u ~ Ο ϟ ĹĹЧИІvgg hN1 hfE CJ OJ QJ aJ hN1 h1z 5CJ OJ QJ aJ "hN1 h r 5>*CJ OJ QJ aJ hN1 h1z CJ OJ QJ aJ "hN1 h r 5CJ OJ QJ \aJ hN1 h r OJ QJ hN1 h r 5OJ QJ hN1 h r CJ OJ QJ aJ hN1 h r 5CJ OJ QJ aJ hN1 h r CJ OJ QJ \aJ "E a z Þ ; < F u ~ ϟ Y ݠ gdN1
! gd r gd r
1$ 7$ 8$ H$ gd r
1$ 7$ 8$ H$ gd r
! 1$ 7$ 8$ H$ gd r D Y ݠ 쵠~n~nn~n~nYI9 h( B*
CJ OJ QJ aJ ph p h< 5B*CJ OJ QJ ph (hl@ hw 5B*CJ OJ QJ aJ ph hN1 hN1 5CJ OJ QJ aJ hN1 hN1 CJ OJ QJ aJ %hN1 hN1 B*CJ OJ QJ aJ ph (hN1 hN1 5B*CJ OJ QJ aJ ph h=C 5>*CJ OJ QJ aJ %hN1 h4F B*
CJ OJ QJ aJ ph p (hN1 h4F 5B*
CJ OJ QJ aJ ph p %hN1 h4F B*CJ OJ QJ aJ ph . ޡ 9 R S z ̢ < gdhZ gd7j gd< gdN1 ˡ ݡ ޡ 8 9 Q R S z ɶuiZG4 %h$ hhZ B*CJ OJ QJ aJ ph %h$ h< B*CJ OJ QJ aJ ph h$ h ? @ `^``gd< `^``gd d gdy! `^``gdy! gd< < gde Y Z [ \ e f g " $ ( * K ] w έ ϭ ҿzlhZZZZlZlG %h5V h d B*CJ OJ QJ aJ ph h d B*CJ OJ QJ ph hy! hy! B*CJ OJ QJ ph !hs=+ h< B*
CJ OJ QJ ph p h< B*CJ OJ QJ ph $hhL h< 5B*CJ OJ QJ ph $hhL h< 5B*
CJ OJ QJ ph p %hhm h< B*CJ OJ QJ aJ ph %hhm he B*CJ OJ QJ aJ ph hhm h3 CJ OJ QJ aJ h3 CJ OJ QJ aJ ϭ Э Ү = > @ k p t w ͱ Ϳ{l`lTl hE= CJ OJ QJ aJ h=C CJ OJ QJ aJ hc!I hB CJ OJ QJ aJ hy! hy! CJ OJ QJ aJ h& CJ OJ QJ aJ hy! h& CJ OJ QJ aJ hy! CJ OJ QJ aJ hy! B*CJ OJ QJ ph h d B*CJ OJ QJ ph h& B*CJ OJ QJ ph !hs=+ h< B*
CJ OJ QJ ph p %h5V h< B*CJ OJ QJ aJ ph @ k ͱ α -
Y Ӵ " $ % @ ̵ ͵ gd3
& F gd v gd v
& F
gd v $
& F
H$ a$gd v gd7 gd7j gdE gdB gd< ͱ α / ; v ò IJ * ˸}maUaUIUIUaU=aI h3 CJ OJ QJ aJ h` CJ OJ QJ aJ h7 CJ OJ QJ aJ h v CJ OJ QJ aJ h7 5B*
CJ OJ QJ ph p $hl@ h@# 5B*
CJ OJ QJ ph p $hl@ hw 5B*
CJ OJ QJ ph p (hl@ h4F 5B*CJ OJ QJ aJ ph %hs=+ hE B*
CJ OJ QJ aJ ph p hE 5B*CJ OJ QJ ph h4F 5B*CJ OJ QJ ph (h5V h< 5B*CJ OJ QJ aJ ph
X Ҵ " # $ % > ? @ F J ˵ ҵ ֵ ı}oaoaoaoaoP !hl@ h6P B*CJ OJ QJ ph h3 B*CJ OJ QJ ph h6P B*CJ OJ QJ ph h3 B*
CJ OJ QJ ph p $hl@ hE 5B*CJ OJ QJ ph $hl@ h4F 5B*CJ OJ QJ ph %hl@ hr# B*CJ OJ QJ aJ ph hr# B*CJ OJ QJ ph %hl@ h7j B*CJ OJ QJ aJ ph h v CJ OJ QJ aJ hN1 h v CJ OJ QJ aJ ͵
" # @ + ^ _ ̹ $ K ߺ ) _ < gdG gd3 gd6P
! " # @ M N ] ^ _ ²qeqeqeYJ9!hl@ h5V B*
CJ OJ QJ ph p hG hQ CJ OJ QJ aJ hQ CJ OJ QJ aJ hG CJ OJ QJ aJ hG hG CJ OJ QJ aJ !hl@ h4F B*
CJ OJ QJ ph p %h% h#(A B*
CJ OJ QJ aJ ph p h3 B*
CJ OJ QJ ph p h3 5B*CJ OJ QJ ph h6P B*
CJ OJ QJ ph p h6P B*CJ OJ QJ ph h3 B*CJ OJ QJ ph %hl@ h4F B*CJ OJ QJ aJ ph ٹ # 1 J X 6 ^ l Ļ ջ ! Ҽ ڼ : ; < P Q ƺƉ}}}}l !hl@ h4F B*CJ OJ QJ ph hdE CJ OJ QJ aJ hdE hdE CJ OJ QJ aJ %hl@ h4F B*CJ OJ QJ aJ ph h*7s h*7s CJ OJ QJ aJ h*7s CJ OJ QJ aJ !hl@ h4F B*
CJ OJ QJ ph p h*7s B*
CJ OJ QJ ph p hG hG CJ OJ QJ aJ hG CJ OJ QJ aJ '_ ֻ ! 6 c ۼ ; < R ܽ : ; < O e 7 gdI < gd3y < gddE < gd*7s < gdG Q R ۽ 9 : ; < B L N O U e ŰzgYH9 hI hI CJ OJ QJ aJ !hl@ h4F B*
CJ OJ QJ ph p h-
< B*
CJ OJ QJ ph p %hl@ h4F B*CJ OJ QJ aJ ph $hl@ hE 5B*CJ OJ QJ ph $hl@ h4F 5B*CJ OJ QJ ph h-
< 5B*CJ OJ QJ ph (hl@ hdE 5B*CJ OJ QJ aJ ph hdE B*
CJ OJ QJ ph p h3y CJ OJ QJ aJ hhm h3y CJ OJ QJ aJ !h% h4F B*CJ OJ QJ ph p z < ) > 6 8 : ; = > @ A C D ` 9 $a$ gdG gdq ^gdI gdI 5 6 7 8 9 ; < > ? A B D E \ ] ^ _ b c d ȹyk j h * UmH nH u hT mH nH uh * j h * Uh9H j h9H U!h5V h4F B*
CJ OJ QJ ph p hq B*
CJ OJ QJ ph p hI hq CJ OJ QJ aJ hq CJ OJ QJ aJ hI CJ OJ QJ aJ hI hI CJ OJ QJ aJ hI hI CJ OJ QJ \aJ ` a b c d 9 5 0 &P :pl@ / =!8"#$% ^M 6 6 6 6 6 6 6 6 6 v v v v v v v v v 6 6 6 6 6 6 > 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 h H 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 p 6 2 & 6 F V f v 2 & 6 F V f v & 6 F V f v & 6 F V f v & 6 F V f v & 6 F V f v & 6 F V f v 8 X V ~ _HmH nH sH tH < ` < N o r m a l CJ _HmH sH tH D A D D e f a u l t P a r a g r a p h F o n t V i V
0 T a b l e N o r m a l :V 4 4
l a ( k (
0 N o L i s t B '` B
I 0 C o m m e n t R e f e r e n c e CJ aJ & & _ 2 6 1$ d d _ 2 5 C
# p@ P ! 01$ ] ^`0 X "X _ 2 4 8
p@ P ! p1$ ] ^p V 2V _ 2 3 5
@ P ! @ 1$ ] ^@ R BR _ 2 2 2
P ! 1$ ] ^ P RP _ 2 1 /
P ! 1$ ] ^ L bL _ 2 0 ,
P ! 1$ ] ^ J rJ _ 1 9 )
P ! 1$ ] ^ F F _ 1 8 &
P ! P1$ ] ^P b b _ 1 7 A
)
p@ P ! 1$ ] ^ d d _ 1 6 C
# p@ P ! 01$ ] ^`0 X X _ 1 5 8
p@ P ! p1$ ] ^p V V _ 1 4 5
@ P ! @ 1$ ] ^@ R R _ 1 3 2
P ! 1$ ] ^ P P _ 1 2 /
P ! 1$ ] ^ L L _ 1 1 ,
P ! 1$ ] ^ J J _ 1 0 )
P ! 1$ ] ^ D D _ 9 & !
P ! P1$ ] ^P ` "` _ 8 A "
)
p@ P ! 1$ ] ^ b 2b _ 7 C #
# p@ P ! 01$ ] ^`0 V BV _ 6 8 $
p@ P ! p1$ ] ^p T RT _ 5 5 %
@ P ! @ 1$ ] ^@ P bP _ 4 2 &
P ! 1$ ] ^ N rN _ 3 / '
P ! 1$ ] ^ J J _ 2 , (
P ! 1$ ] ^ H H _ 1 ) )
P ! 1$ ] ^ B B _ & *
P ! P1$ ] ^P 0 0 D e f a u l t P a r a F O F
W P _ P l a i n T e x t , 1$ OJ QJ CJ < o< P l a i n T e x t C CJ OJ QJ 8 @ 8
/ I 0 C o m m e n t T e x t . CJ : : . I 0 C o m m e n t T e x t C h a r @ j@@
1 I 0 C o m m e n t S u b j e c t 0 5\F oF 0 I 0 C o m m e n t S u b j e c t C h a r 5\H @ "H
3 I 0 B a l l o o n T e x t 2 CJ OJ QJ ^J aJ N o1N 2 I 0 B a l l o o n T e x t C h a r CJ OJ QJ ^J aJ . X`A.
@ E m p h a s i s 6]* W`Q*
` S t r o n g 5\< ^@ b< K% 0 N o r m a l ( W e b ) 6 PJ aJ 4 r4 8 G 0 H e a d e r
7
H$ 2 o2 7 G 0 H e a d e r C h a r CJ 4 @ 4 : G 0 F o o t e r
9
H$ 2 o2 9 G 0 F o o t e r C h a r CJ 6 U`6 G H y p e r l i n k >*B*ph < P@ < = Y B o d y T e x t 2 < B*ph F oF < Y B o d y T e x t 2 C h a r
B*CJ ph : O : Y T i t l e 1 > d d [$\$ aJ 0 O 0 Y t i t l e 1 ? CJ aJ > O > Y d e t a i l s 1 @ d d [$\$ aJ o Y j r n l 6 O "6 Y d e s c B d d [$\$ aJ < O 2< Y d e t a i l s C d d [$\$ aJ B oAB Y a p p l e - c o n v e r t e d - s p a c e : O R: Y T i t l e 3 E d d [$\$ aJ : O b: Y T i t l e 4 F d d [$\$ aJ : O r: Y T i t l e 5 G d d [$\$ aJ 8 O 8 Y t i t l e H d d [$\$ aJ 8 O 8 v| l i n k s I d d [$\$ aJ @ @ @ G L i s t P a r a g r a p h
J ^ T `T r
N o S p a c i n g K $ CJ OJ PJ QJ _HaJ mH sH tH o Q i l PK ! [Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;r ØJB+$G]7O٭V$ !)O^rC$y@ /yH*)UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSe bORD۫qu gZo~ٺlAplxpT0+[}`j zA V2Fi@qv֬5\|ʜ̭NleXd sjcs7f
W+Ն7` g ȘJj|h(KD-
dXiJ؇(x$( :;˹! I_TS 1?E ??ZBΪmU/ ?~xY'y5g&/ɋ>GMGeD3Vq%'#q$8K )fw 9:ĵ
x}rxwr:\TZaG*y8IjbRc|XŻǿI
u3KGnD 1NIBs
RuK>V.E L+M2#'fi ~V vl{u8z H
* :( W ☕
~JTe\O*tHGHY }KNP*ݾ˦ TѼ9/#A7qZ $*c?qUnwN%Oi4 =3N)cbJ
uV4(Tn
7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5 qpN8KGbe
Sd̛\17 pa>SR!
3 K4'+rzQ
TTIIvt]Kc⫲K#v5+|D~ O@%\w_nN[L9KqgVhn
R!y+Un;*&/HrT >>\
t=.Tġ
S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y ; ̠[MCۿhf]o{oY=1kyV V5E8Vk+֜\80X4D)!!?*|fv
u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/ PK !
ѐ ' theme/theme/_rels/themeManager.xml.relsM
0wooӺ&݈Э5
6?$Q
,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{ P8g/ ]QAsم(#L[ PK- ! [Content_Types].xmlPK- ! ֧ 6 0 _rels/.relsPK- ! ky theme/theme/themeManager.xmlPK- ! 0C) theme/theme/theme1.xmlPK- !
ѐ ' theme/theme/_rels/themeManager.xml.relsPK ]
d t * * * - < 6 _
& . %1 t3 5 =8 9 : = 5@ [C yE J 4N P ZR T "X ] #b &g 1m p Cs lu x J| ; D a e H |
՚ ϭ ͱ Q d c e f h i k l n o q r s u v w x y { | } ~ " '1 ; G U v X E ! @ ͵ _ ` d d g j m p t z :( t( ( * + U+ B, |, - / / )0 1 >1 1 2 83 3 4 4 A5 5 5 j6 '7 a7 7 w8 8 V9 : R: : Z; ; ; O RO O P 8Q Q kR R ^S ST T U V JV V W W pX iY Y #Z [ [ \ ] ] ^ _ ` ` #b ^b b d Od d e f qf dg g
h j >j j k l jl lm m Ln n 5o o p p Pq Rr r
s t +u u v w w x &y y z Ez z S{ { | h} } } i 8 d XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX $ & - ! 8 @ 0 (
B
S ? v ' . < B G P
T
W
N S
;
?
P T s x 7 < r w t x ' 0 S W & 0 u V ` P Z G N c f ! # & @ E R \ ) 1 5 9 = C G M Q V Z _ } ` e i q {! ! ! ! ! !
" " " " " " # # # $# # # # # U$ Y$ % % % % % % ~& & & & ' ' ' ' ' ' ' ' ' ' ( ( ( ( ( ( ) ) 0) 7) ;) D) H) P) `) e) i) p) I* L* a* e* w* * * * J+ T+ ^+ a+ u+ y+ + + + + + + + + ,, 5, , , 6- :- b- i- m- v- z- - - - - - - - - - - - - - - - . . . . . / / / / / / / 8/ > > > > > > > > > > > > > ? ? ? ? ? ? !? *? ? ? ? ? ? ? @ "@ '@ -@ <@ B@ F@ K@ @ @ A A A A JA RA jA sA A A B B B B $B *B /B 7B DB IB dB iB B B B B +C .C /C 3C UC \C iC nC rC yC C C C C C C C C ~D D D D D D D D D D D D D D D D E E &E -E 1E Y BY KY OY YY ^Y cY &Z )Z @ A C D b e X
b
\ _ e g a b 1 1 1 1 3 3 : : ? ? }@ @ /K 2K FK IK YL \L O O O O Q Q Q Q vS yS 6U 9U QU TU V V W W X X @ A C D b e 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 *W *W X X Z Z \ \ &_ &_ ` ` ,c ,c 2e 2e f f h h Ck Ck l l n n c e 8 D _ e *W *W X X Z Z \ \ &_ &_ ` ` ,c ,c 2e 2e f f h h Ck Ck l l n n c e 8 : ; = > @ A C D _ b e D,> "bq ab 4Ny os(. D MW(b
4 /\D ~O Qx l S %" 8]Jc!^ yt a!x Xq Qieg rye x h Xa " " 1 !THe x h [a /8`R(L $RX`c:U 2& 2; =`c:U " " m!~[ I eg s; 4C"k " " =;#!TH r]F$ ]+(% [ z]&4+- w+ Ye,t&a " " 4+-3Sn 3;/NU 761Jc!^ " " WF G G 9H c!I fK hL mN $N BO #dO 6P VnQ tQ < V 5V cW ~X JE[ }F` Bb c 2d ;e oe hm om <+n g m ) Q j p % ;^
F =l $ & U x_ t +2 ~ U q y! Q9 l S " j: Z y N@ Y 3 G hZ c~ ( q I Z G 8 : @ g g g g d @ U n k n o w n G * Ax T i m e s N e w R o m a n 5 S y m b o l 3. * Cx A r i a l 9 G a r a m o n d 7. @ C a l i b r i 5. . [` ) T a h o m a ?= * Cx C o u r i e r N e w ; W i n g d i n g s A $ B C a m b r i a M a t h # A 9XguXgfVg
!
` U !
` U ! 2 ػ ػ I1hn Kq HX $P s=+ 2 ! x x W P A n d r e w L e e R o s s , A s h l e y <
Oh +'0 |
, 8 D
P \ d l t W P Andrew Lee Normal.dotm Ross, Ashley 3 Microsoft Office Word @ e @ @ ^Z @ b
! ՜. +,D ՜. +,8 h p
Johns Hopkins U ` ػ Title 8 @ _PID_HLINKS A ^ z - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 7 0 4 3 4 1 ] w - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 0 8 3 4 7 4 W t - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 6 6 1 8 9 8 ! 2 q , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 6 1 4 0 2 6 ! 1 n , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 4 7 7 6 0 9 ! 5 k , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 5 0 3 1 1 0 # 2 h , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 1 2 3 1 2 0 U
e - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 5 2 8 8 1 1 Z
b - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 5 9 1 5 7 7 Y _ - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 6 6 2 6 4 7 _ \ - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 7 0 9 8 8 9 Z
Y - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 7 3 5 0 1 8 Y V - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 7 3 6 3 1 8 T S - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 0 5 8 7 5 7 \ P - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 0 9 2 6 7 0 W M - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 1 1 7 3 8 7 ] J - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 1 4 0 4 5 9 [ G - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 1 8 7 4 4 9 ] D - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 3 3 0 6 7 6 S A - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 3 4 1 5 8 9 X > - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 3 5 0 5 2 0 W ; - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 3 5 8 6 5 5 [ 8 - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 4 0 0 1 6 7 ] 5 - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 4 1 7 9 7 9 ] 2 - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 4 3 7 1 7 0 [ / - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 4 4 6 5 0 6 X
, - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 4 8 1 4 4 0 ^ ) - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 4 8 4 0 7 5 ^ & - h t t p s : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 8 4 9 4 0 7 3 ) 5 # , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 6 8 8 1 9 0 % 3 , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 7 3 1 6 7 2 + 5 , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 4 9 3 2 0 3 % 4 , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 6 3 1 6 1 6 ' 7 , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 4 1 4 6 5 6 6 , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 4 4 3 4 3 2 - 4 , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 4 4 6 9 4 5 . 4 , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 1 9 5 7 2 3 + 5 , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 6 2 9 4 2 1 1 " < , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 5 9 8 6 9 1 4 ? , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 5 8 6 4 5 1 8 $ 8 , h t t p : / / w w w . n c b i . n l m . n i h . g o v / p u b m e d / 2 5 9 6 4 1 7 5
! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~
" ! R o o t E n t r y F uաb 1 T a b l e ~ W o r d D o c u m e n t 7t S u m m a r y I n f o r m a t i o n ( D o c u m e n t S u m m a r y I n f o r m a t i o n 8 T M a c r o s
%áb %áb V B A %áb %áb d i r
! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H J K L M N O R 0* pH d ProjectQ ( @=
l XH[ J<
rstdole>s t d o l eP
h %^ * \G{00020430- C
0046}# 2.0#0#C: \Windows \SysWOW64\e2.tlb #OLE Automation ` ENormalENCr m aQF * \C
%A[ !OfficgO f i cg !G{2 DF8D04C- 5BFA-101@B-BDE5gAjAe42gg ram File s (x86)\@Common \ Microsof t Shared \OFFICE1 4\MSO.DL L#P 15.0 Ob Li`brary ' zMSF@Cs> M S FDHs 3@ eD 452EE1-E08F1A-8 -02608C4 D0BB4eFMl20L'B @r&/ ; "1 ă} Ã00}#0F# 0 @ 74D1C9 67-FA6F- 4F47-9FD 0-9ED401 E8CFB Us ers\aXs2 \AppData \Local\T emp\Word8.0@[/.ex dH\4" .E
.`M ݈ qm ThisDocumentG T@i s Ddc ue n@* 2 ` H 1u "E,3""+ qm3 x T h i s D o c u m e n t
_ V B A _ P R O J E C T : P R O J E C T I P R O J E C T w m P ) ME ( S" S S" < ( 1 N o r m a l . T h i s D o c u m e n t 8 ( % H x Attribut e VB_Nam e = "Thi sDocument"
Bas1Normal.VGlobal!SpaclFalse Creatabl Pre decla Id Tru
BExpose Temp lateDeriv$Custom izC1 a * \ G { 0 0 0 2 0 4 E F - 0 0 0 0 - 0 0 0 0 - C 0 0 0 - 0 0 0 0 0 0 0 0 0 0 4 6 } # 4 . 1 # 9 # C : \ P R O G R A ~ 2 \ C O M M O N ~ 1 \ M I C R O S ~ 1 \ V B A \ V B A 7 \ V B E 7 . D L L # V i s u a l B a s i c F o r A p p l i c a t i o n s * \ G { 0 0 0 2 0 9 0 5 - 0 0 0 0 - 0 0 0 0 - C 0 0 0 - 0 0 0 0 0 0 0 0 0 0 4 6 } # 8 . 5 # 0 # C : \ P r o g r a m F i l e s ( x 8 6 ) \ M i c r o s o f t O f f i c e \ O f f i c e 1 4 \ M S W O R D . O L B # M i c r o s o f t W o r d 1 4 . 0 O b j e c t L i b r a r y * \ G { 0 0 0 2 0 4 3 0 - 0 0 0 0 - 0 0 0 0 - C 0 0 0 - 0 0 0 0 0 0 0 0 0 0 4 6 } # 2 . 0 # 0 # C : \ W i n d o w s \ S y s W O W 6 4 \ s t d o l e 2 . t l b # O L E A u t o m a t i o n * \ C N o r m a l * \ C N o r m a l %A[ 4* \ G { 2 D F 8 D 0 4 C - 5 B F A - 1 0 1 B - B D E 5 - 0 0 A A 0 0 4 4 D E 5 2 } # 2 . 5 # 0 # C : \ P r o g r a m F i l e s ( x 8 6 ) \ C o m m o n F i l e s \ M i c r o s o f t S h a r e d \ O F F I C E 1 4 \ M S O . D L L # M i c r o s o f t O f f i c e 1 5 . 0 O b j e c t L i b r a r y * \ G { 0 D 4 5 2 E E 1 - E 0 8 F - 1 0 1 A - 8 5 2 E - 0 2 6 0 8 C 4 D 0 B B 4 } # 2 . 0 # 0 # C : \ W i n d o w s \ S y s W O W 6 4 \ F M 2 0 . D L L # M i c r o s o f t F o r m s 2 . 0 O b j e c t L i b r a r y * \ G { 7 4 D 1 C 9 6 7 - F A 6 F - 4 F 4 7 - 9 F D 0 - 9 E D 4 0 1 E 8 C F B 6 } # 2 . 0 # 0 # C : \ U s e r s \ a r o s s 2 \ A p p D a t a \ L o c a l \ T e m p \ W o r d 8 . 0 \ M S F o r m s . e x d # M i c r o s o f t F o r m s 2 . 0 O b j e c t L i b r a r y .E
.`M XH[ qm T h i s D o c u m e n t 0 1 5 a a 8 e f 9 b # T h i s D o c u m e n t 3 W_b BҪ+\j ` & Wordk VBA Win16~ Win32 Win64x Mac VBA6# VBA7# Project- stdole` Normal Officeu MSFormsC ThisDocument< _Evaluate Documentj ` #
ID="{0550BB44-121A-47AD-B1F1-490F20F3DEC1}"
Document=ThisDocument/&H00000000
Name="Project"
HelpContextID="0"
VersionCompatible32="393222000"
CMG="5A58967EF482F482F482F482"
DPB="B4B678D8883389338933"
GC="0E0CC2824686A187A1875E"
[Host Extender Info]
&H00000001={3832D640-CF90-11CF-8E43-00A0C911005A};VBE;&H00000000
&H00000002={000209F2-0000-0000-C000-000000000046};Word8.0;&H00000000
ThisDocument T h i s D o c u m e n t
F Microsoft Word 97-2003 Document
MSWordDoc Word.Document.8 9q C o m p O b j Q r